

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Diagnostic Accuracy of CCTA-derived versus Angiography-derived Quantitative Flow Ratio (CAREER) Study: Rationale and Design

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055481
Article Type:	Protocol
Date Submitted by the Author:	16-Jul-2021
Complete List of Authors:	Weng, Tingwen; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Gan, Qian; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Li, Zehang; Shanghai Jiao Tong University, School of Biomedical Engineering Guan, Shaofeng Han, Wenzheng; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Zhai, Xinrong; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Li, Ming; Huadong Hospital Affiliated to Fudan University, Department of Radiology Qi, Lin; Huadong Hospital Affiliated to Fudan University, Department of Radiology Li, Cheng; Huadong Hospital Affiliated to Fudan University, Department of Radiology Chen, Yang; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Zhang, Liang; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Chang, Xifeng; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Tu, Shengxian; Shanghai Jiao Tong University QU, XINKAI; Huadong Hospital Affiliated to Fudan University, Department of Cardiology
Keywords:	Adult cardiology < CARDIOLOGY, Coronary heart disease < CARDIOLOGY, Coronary intervention < CARDIOLOGY, Cardiomyopathy < CARDIOLOGY, Ischaemic heart disease < CARDIOLOGY

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Title: Diagnostic Accuracy of CCTA-derived versus Angiography-derived**  
5  
6 **Quantitative Flow Ratio (CAREER) Study: Rationale and Design**  
7  
8  
9

10  
11  
12  
13  
14 Running title: Diagnostic Accuracy of CAREER Study: Rationale and Design  
15  
16

17  
18  
19 TingwenWeng,<sup>a\*</sup>MD., Qian Gan, <sup>a\*</sup>MD. PhD.,Zehang Li, <sup>b</sup>BSc., Shaofeng Guan,  
20  
21 <sup>a</sup>MD.PhD.,Wenzheng Han, <sup>a</sup>MD.PhD., XinrongZhai, <sup>a</sup>MD., Ming Li,<sup>c</sup>MD.PhD, Lin  
22  
23 Qi, <sup>c</sup> MD., Cheng Li, <sup>c</sup> MD., Yang Chen, <sup>a</sup> MD., Liang Zhang, <sup>a</sup> MD., Xifeng Chang, <sup>a</sup>  
24  
25 MD., ShengxianTu,<sup>b</sup> PhD., Xinkai Qu <sup>a</sup>MD.PhD.  
26  
27  
28  
29  
30  
31  
32  
33  
34

35 a Department of Cardiology, Huadong Hospital Affiliated to Fudan University,  
36  
37 Shanghai, China,  
38

39  
40 b Biomedical Instrument Institute, School of Biomedical Engineering, Shanghai Jiao  
41  
42 Tong University, Shanghai, China,  
43  
44

45 c Department of Radiology, Huadong Hospital Affiliated to Fudan University,  
46  
47 Shanghai, China.  
48  
49

50  
51  
52  
53 \*Equal contributors. Tingwen Weng and Qian Gan contributed equally to this work.  
54  
55  
56  
57

58 **Corresponding author:**  
59  
60

1  
2  
3  
4 Xinkai Qu M.D

5  
6 Huadong Hospital Affiliated to Fudan University

7  
8  
9 221 Yan'an W Rd, Jing'an District, Shanghai, China, 200040

10  
11 E-mail: [qxkhuadong@sina.com](mailto:qxkhuadong@sina.com) Phone: +86 13916320399

12  
13  
14 Shengxian Tu M.D

15  
16 Biomedical Instrument Institute, School of Biomedical Engineering, Shanghai Jiao

17  
18  
19 Tong University, Shanghai, China,

20  
21  
22 E-mail: [sxtu@sjtu.edu.cn](mailto:sxtu@sjtu.edu.cn) Phone: +86 13681841194

## Abstract

**Introduction:** Coronary computed tomography angiography (CCTA)-derived quantitative flow ratio (CT-QFR) is a novel non-invasive technology to assess the physiological significance of coronary stenoses, which enables fast and on site computation of fractional flow reserve (FFR) from CCTA images. The objective of this investigator-initiated, prospective, single-center clinical trial is to evaluate the diagnostic performance of CT-QFR with respect to angiography-derived QFR, using FFR as the reference standard.

**Methods and analysis:** A total of 216 patients who have at least 1 lesion with a diameter stenosis of 30% to 90% in an artery with  $\geq 2.0$  mm reference diameter will be enrolled in the study. FFR will be measured during invasive coronary angiography. CT-QFR, and QFR will be assessed in two independent core laboratories in blinded fashion. The primary endpoint is the diagnostic accuracy of CT-QFR in identifying hemodynamically significant coronary stenosis with FFR as the reference standard. Major secondary endpoint is the non-inferiority of CT-QFR compared with QFR in the patients without extensively calcified lesions.

**Ethic and Dissemination:** This study will be the first study to prospectively validate the diagnostic accuracy of CT-QFR compared with QFR, using FFR as the reference standard.

## Article summary

### Strengths and limitations of this study:

- This study will lay the foundation for future studies to look at the potential

1  
2  
3  
4 value of CT-QFR technology in patients management. Through CT-QFR  
5  
6 measurement, outpatients can receive coronary artery functional evaluation  
7  
8 while undergoing CCTA Examination.  
9  
10

- 11  
12 ➤ It will greatly reduce unnecessary invasive coronary angiography and  
13  
14 coronary interventions if the study achieves the expected objectives.  
15  
16  
17 ➤ Unfortunately, due to the tight schedule and insufficient funding, a  
18  
19 multi-center study cannot be conducted.  
20  
21  
22  
23  
24

25 **Key words:** Coronary computed tomography angiography- derived quantitative flow  
26  
27 ratio ( CT-QFR ) ; Angiography-derived quantitative flow ratio ( QFR ) ;  
28  
29 Diagnostic accuracy ; Non-inferiority  
30  
31

32 **Trial registration:** ClinicalTrials.gov Identifier: NCT04665817  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Coronary computed tomography angiography (CCTA) is a noninvasive test that enables visualization of coronary anatomy and the characteristics of arterial plaques with high sensitivity and negative predictive value <sup>[1]</sup>. However, conventional CCTA does not allow for physiological assessment of coronary stenosis<sup>[2]</sup>. Fractional flow reserve (FFR) is the current gold standard for evaluating the physiological significance of coronary stenosis in the catheterization laboratory <sup>[3]</sup>. An FFR-guided revascularization strategy was validated with improved clinical outcomes and cost-effectiveness compared to a traditional invasive coronary angiography-guided strategy <sup>[4-7]</sup>. The use of FFR is supported by both European guidelines (Class I, Level of Evidence: A) and American guidelines (Class IIa, Level of Evidence: A) in assessing coronary stenosis and to guide revascularization<sup>[8]</sup>. However, the adoption of FFR was limited due to prolonged procedural time, increased cost, patient discomfort, and operator's confidence in visual assessment from coronary angiograms.

Several computational FFR methods were developed to overcome the above limitations. Quantitative flow ratio (QFR), a new method for fast computation of FFR based on invasive coronary angiography (ICA) and empirical fluid dynamic equations was recently developed<sup>[9]</sup>. The overall diagnostic concordance between QFR and FFR was reported as 87% in a recent meta-analysis of prospective clinical studies<sup>[13]</sup>.

More recently, CCTA-derived QFR, namely CT-QFR, has been developed as a method for fast computation of FFR from CCTA images based on previously validated QFR algorithm. A recent retrospective and observational study

1  
2  
3  
4 demonstrated a good diagnostic concordance of 87% [14]. In addition, its analysis time  
5  
6 has been reduced to less than 5 minutes per patient on an off-the-shelf work station.  
7  
8  
9 The diagnostic accuracy of this CT-QFR software version for on-site evaluation of  
10  
11 coronary stenosis severity remains unknown. Furthermore, the difference in the  
12  
13 diagnostic performance of QFR when applied to noninvasive CCTA images and to  
14  
15 ICA has not been studied. We are therefore planning to prospectively validate the  
16  
17 diagnostic performance of on-site CT-QFR analysis compared with QFR, using FFR  
18  
19 as the reference standard.  
20  
21  
22  
23  
24  
25  
26

## 27 **Methods and analysis**

### 28 **Study design**

29  
30  
31  
32 This study is an investigator-initiated, prospective, single-center clinical trial to  
33  
34 validate the diagnostic performance of on-site CT-QFR using FFR as the reference  
35  
36 standard. The study is conducted in accordance with the ethical principles of the  
37  
38 Declaration of Helsinki. The study protocol was approved by the Ethics Committee of  
39  
40 Huadong Hospital Affiliated to Fudan University. Before the study starts, written  
41  
42 informed consent form will be obtained from patients willing to participate in the  
43  
44 study and approved by the institutional review board/independent ethics committee of  
45  
46 Huadong Hospital Affiliated to Fudan University (2020K192). The protocol of the  
47  
48 trial has been registered at <http://clinicaltrials.gov> (NCT04665817).  
49  
50  
51  
52  
53  
54  
55  
56  
57

### 58 **Study objectives**



1  
2  
3  
4 The primary endpoint of the study is the patient-level diagnostic accuracy of  
5  
6 on-site CT-QFR in identifying physiologically significant coronary artery stenosis,  
7  
8 using FFR as the reference standard. Major secondary end point is the non-inferiority  
9  
10 of CT-QFR compared with QFR in the vessels without extensively calcified lesions  
11  
12 defined by the combination of a cross-sectional calcium arc  $>90^\circ$  and a thickness  $>1.5$   
13  
14 mm. Other secondary objectives of the study will include the following. (1) Other  
15  
16 common measures of diagnostic performance of CT-QFR, including sensitivity,  
17  
18 specificity, positive predictive value (PPV), and negative predictive value (NPV) at  
19  
20 the patient level compared with FFR as the reference standard. (2) Correlation  
21  
22 between CT-QFR and FFR. (3) The comparison of the discrimination ability  
23  
24 between CT-QFR, CCTA-derived percent diameter stenosis (CTA-DS%), and  
25  
26 QCA-derived DS% for identifying physiologically significant stenosis with FFR as  
27  
28 the reference standard.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **Patient population**

41  
42  
43 Patients with stable or unstable angina pectoris or non-acute phase of myocardial  
44  
45 infarction who are undergoing CCTA examination and scheduled for coronary  
46  
47 angiography within 30 days will be screened. Inclusion criteria are: (1) at least 1  
48  
49 lesion with DS% between 30% and 90% in a coronary artery with a  $\geq 2.0$ mm  
50  
51 reference vessel diameter by visual estimation; (2) invasive coronary angiography  
52  
53 performed less than 30 days after CCTA; (3) age over 35 years but less than or equal  
54  
55 to 85 years. Exclusion criteria are: (1) prior percutaneous coronary intervention (PCI)  
56  
57  
58  
59  
60

1  
2  
3  
4 or coronary artery bypass graft (CABG) of the interrogated lesion; (2) myocardial  
5  
6 bridge involved in the interrogated vessel; (3) presence of collateral flow; (4) severe  
7  
8 heart failure (NYHA  $\geq$ III); (5) known severe renal failure (eGFR $<$ 30 ml/min/1.73m<sup>2</sup>);  
9  
10 (6) contraindicated to use contrast agents, beta blockers, nitrates or adenosine drugs;  
11  
12 (7) Recent prior myocardial infarction within 1 month of CCTA; (8) low image  
13  
14 quality CCTA or coronary angiography to be assessed such as motion artifacts, poor  
15  
16 filling of contrast agent, etc.; (9) any factors that affect the image quality of CCTA  
17  
18 and coronary angiography, such as frequent premature contractions, atrial fibrillation,  
19  
20 etc.  
21  
22  
23  
24  
25  
26  
27  
28  
29

### 30 **Statistical hypotheses and Sample Size Calculation**

31  
32 The primary endpoint is the diagnostic accuracy of CT-QFR $\leq$ 0.8 to identify  
33  
34 hemodynamically significant coronary stenosis with FFR $\leq$ 0.8 as the reference  
35  
36 standard. The trial is powered for testing significance of the primary endpoint. The  
37  
38 primary null and alternative hypotheses to be tested are H<sub>0</sub>, diagnostic accuracy of  
39  
40 CT-QFR $\leq$ 0.72, and H<sub>1</sub>, diagnostic accuracy of CT-QFR  $>$  0.72. Estimates for the  
41  
42 sample size calculation are based on the results from the retrospective study of  
43  
44 CT-QFR<sup>[14]</sup>, where an accuracy of 87% at patient level was found. In this prospective  
45  
46 study, the accuracy is conservatively estimated as 82% for consecutively enrolled  
47  
48 patient population, and with a target value set as 72%, which is chosen to be higher  
49  
50 than the one in the DeFACTO study<sup>[15]</sup>. The sample size is analysed for paired  
51  
52 proportions using the following formula:  
53  
54  
55  
56  
57  
58  
59  
60

$$N = \frac{[Z_{1-\alpha/2}\sqrt{P_0(1-P_0)} + Z_{1-\beta}\sqrt{P_T(1-P_T)}]^2}{(P_T - P_0)^2}$$

With power = 0.90, two-tailed alpha = 0.05, a total of 188 patients with paired CT-QFR and FFR are required to reject the null hypothesis for diagnostic accuracy. To account for incomplete CT-QFR/CT-DS%/FFR/QFR/QCA data of 15% at most, a total of 216 patients need to be enrolled.

The major secondary endpoint is to validate the non-inferiority of CT-QFR compared with QFR in the patients without extensively calcified lesions. Analyzed by the enrollment of 216 patients, about 158 patients will be calculated according to the proportion, 26.9%, of extensively calcified lesions from the retrospective study<sup>[14]</sup>. It will be tested for the capability in achieving the major secondary endpoint. The accuracy of 89.5% for CT-QFR in non-severe calcified lesions<sup>[14]</sup> and the accuracy of 92.7% for QFR<sup>[10]</sup> are used to calculate the sample size. We set the non-inferiority threshold as 15%. It will be analyzed by the following formula:

$$N_T = \frac{(Z_{1-\alpha/2} + Z_{1-\beta})^2 [P_C(1 - P_C) + P_T(1 - P_T)]}{(D - \Delta)^2}$$

With power = 0.90, two-tailed alpha = 0.05, a total of 122 patients are required to validate the non-inferiority. To account for incomplete CT-QFR/CTA-DS%/FFR/QFR/QCA data of 15% at most, 141 patients need to be enrolled. Therefore, 158 patients without extensively calcified lesions meet the sample size of the major secondary endpoint. Therefore, the sample size is set as 216 patients to satisfy the requirements for validating both primary and major secondary endpoints.

### **CCTA and CTA-DS% Analysis**

Coronary computed tomographic angiography is performed on a dual-source CT system (SOMATOM Drive; Siemens Healthineers, Erlangen, Germany) or a 256 detector row scanners CT system (Revolution CT; GE Healthcare) with prospective or retrospective electrocardiographic gating in accordance with Society of Cardiovascular Computed Tomography guidelines<sup>[16]</sup>. Image interpretation of CCTA is conducted in blinded fashion by an experienced investigator. Images with coronary artery stenosis detected visually will be further analyzed (CtaPlus; version 1.0, Pulse Medical Imaging Technology, Shanghai, China). Coronary stenosis will be quantified by using the following parameters: (i) the minimal lumen area (MLA) and the minimal lumen diameter (MLD), and (ii) the percentage diameter stenosis (DS%) and the percentage area stenosis (AS%).

### **CT- QFR Computation**

CT-QFR computation is performed by experienced analysts using a recently developed software package (CtaPlus, version 1.0; Pulse Medical Imaging Technology, Shanghai, China), blinded to both QFR and FFR data. Detailed methodologies for CT-QFR computation have been published previously<sup>[14]</sup>. A recent upgrade in the CT-QFR algorithm integrated deep learning technique into coronary segmentation method to improve the computation efficiency. Manual corrections are allowed if the automated delineation lumen contour is sub-optimal, particularly at the

1  
2  
3  
4 segment with calcified plaques. All coronary artery segments with reference lumen  
5  
6 diameter  $\geq 1.5$  mm are analyzed. Subsequently, all the delineated coronary branches  
7  
8 are automatically merged for reconstruction of entire coronary tree, based on which  
9  
10 the healthy reference lumen is also reconstructed. Finally, CT-QFR value at each  
11  
12 position of the coronary tree is computed using the previous validated QFR  
13  
14 algorithm<sup>[9, 17]</sup>.  
15  
16  
17  
18  
19  
20  
21

### 22 **Coronary Angiography**

23  
24 Coronary angiography is performed by using a 5- or 6-F catheter with a  
25  
26 transfemoral or transradial approach. All patients will receive intravenous injection of  
27  
28 heparin 100 IU/kg before angiography. Contrast media (Omnipaque 350 injection, GE  
29  
30 Healthcare, Shanghai, China) is injected manually with a forceful and stable injection.  
31  
32 Coronary angiograms are obtained from standard series of 6 to 8 projections for the  
33  
34 left coronary artery and 2 or 3 projections for the right coronary artery by using a  
35  
36 monoplane or biplane radiographic system (AXIOM Artis FC and Artis zee Biplane  
37  
38 MN, Siemens) at 15 frames/s. All images are digitally stored for analysis.  
39  
40  
41  
42  
43  
44  
45  
46  
47

### 48 **FFR Measurement**

49  
50 Intracoronary pressure is measured by using a RadiAnalyzer Xpress instrument  
51  
52 and Certus pressure wire (St. Jude Medical, Plymouth, Minnesota). The pressure  
53  
54 guidewire is introduced into the coronary artery and positioned distal to the coronary  
55  
56 stenosis. The position of the sensor of the pressure guide wire is recorded on cine  
57  
58  
59  
60

1  
2  
3  
4 fluorography. Hyperemia is induced by adenosine-5'-triphosphate (ATP) infusion  
5  
6 (160 lg/kg/minute) through an antecubital vein over a minimum of 2 minutes. During  
7  
8 steady-state hyperemia, mean proximal aortic pressure, mean intracoronary pressure  
9  
10 distal to the target stenosis are measured. Subsequently, the pressure guide wire is  
11  
12 slowly pulled back from the most distal to the proximal part of the artery by manual  
13  
14 procedure during steady-state maximal hyperemia. If the pressures are not equalized  
15  
16 at the end of the pullback (i.e. the pressure drift  $|P_a - P_d| > 3$  mmHg), the whole FFR  
17  
18 measurements should be repeated from the beginning.  
19  
20  
21  
22  
23  
24  
25  
26

### 27 **QCA Analysis and QFR Computation**

28  
29  
30 Quantitative coronary angiographic (QCA) analysis and QFR computation are  
31  
32 performed in blinded fashion by using the recently developed QFR analysis system  
33  
34 (AngioPlus Core; Pulse Medical Imaging Technology, Shanghai, China). The  
35  
36 computational methods were previously described<sup>[9, 17]</sup>. Same as CT-DS% analysis,  
37  
38 QCA analysis includes following parameters: (i) MLA and MLD, and (ii) DS% and  
39  
40 AS%. It will be analyzed by well-trained technicians who have successfully  
41  
42 completed QFR training. Before QFR analysis, the technicians will be informed about  
43  
44 the location where the operators measured FFR so that QFR could be measured at the  
45  
46 same vessel site. The QFR measure will be performed on the system placed in the  
47  
48 control room. The investigators are blinded to the FFR results.  
49  
50  
51  
52  
53  
54  
55

### 56 **Study flowchart**

57  
58 A study flowchart is shown in Figure 1.  
59  
60

## Statistical Analysis

Continuous variables are presented as mean±SD, and categorical variables are presented as counts and percentages. Sensitivity, specificity to predict functionally significant stenosis (FFR≤0.80). The performance of QFR≤0.80 and CT-QFR≤0.80 for predicting FFR≤0.80 will be assessed by using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (+LR), negative likelihood ratio (-LR), and diagnostic accuracy, together with their 95% confidence intervals (CIs). Pearson correlation or spearman's correlation will be used to quantify the correlations between QFR, CT-QFR, and FFR. Agreements between QFR, CT-QFR, and FFR will be assessed by Bland-Altman plot. The Bland-Altman plot depicts the differences of each pair of measurements versus their mean values with reference lines for the mean difference of all paired measurements. The limits of agreement are defined as mean±1.96 SD of absolute difference. The ROC curve analysis will be performed to assess area under the curve (AUC) of CT-QFR, QFR, CT-derived %DS and QCA derived %DS for predicting FFR≤0.80. The ROC curves will be compared by using the DeLong method. A two-side p value <0.05 is considered to indicate statistical significance.

## Current status

The study has been approved by the Ethics Committee of Huadong Hospital Affiliated to Fudan University. Five analysts have successfully completed the International Course on Coronary Image Analysis and Computational Physiology which covers FFR, QFR and CT-QFR. All of them have obtained qualification

certificates for relevant analysis. Recruitment is ongoing at Huadong Hospital Affiliated to Fudan University, Shanghai, China. At present, 35 participants have been recruited to the study.

### **Ethics and dissemination**

The CAREER study will for the first time prospectively evaluate the diagnostic accuracy of on-site CT-QFR analysis in identifying patients with physiologically significant coronary stenosis. In addition, diagnostic performance of CCTA-based versus angiography-based QFR in vessels without significantly calcified lesions will be compared. The study findings will provide pivotal data to support the clinical applications of CT-QFR in management of CAD patients.

The previously presented FFR computation method derived from computed tomography ( $FFR_{CT}$ ), a non-invasive technology, is a computational fluid dynamics modeling technique that enables the calculation of FFR from a coronary computed tomographic angiographic dataset<sup>[19]</sup>. The diagnostic performance of  $FFR_{CT}$  has been validated in several multi-center prospective clinical trials <sup>[20-22]</sup>. The application of  $FFR_{CT}$  can reduce unnecessary invasive coronary angiography <sup>[23, 24]</sup>. However, it heavily relies on the quality of the underlying computational models and sophisticated boundary conditions and required a few hours for computation<sup>[22]</sup>. Moreover, severe calcified lesions might affect the calculation results of  $FFR_{CT}$  <sup>[25]</sup>.

Recently, a novel technique for the rapid computation of FFR from radiographic coronary angiography, named QFR, was accomplished by estimating the pressure



1  
2  
3  
4 drop due to coronary stenosis according to coronary lumen morphology and virtual  
5  
6 hyperemic flow derived from contrast frame count without use of pressure wire and  
7  
8 drug-induced hyperemia<sup>[9]</sup>. The diagnostic performance of this minimally invasive  
9  
10 technique has been validated by several studies<sup>[9-12]</sup>. More recently, the novel QFR  
11  
12 algorithm has been applied to CCTA-images, and CCTA-derived QFR (namely  
13  
14 CT-QFR), has been derived as a non-invasive technology to assess the physiological  
15  
16 significance of coronary stenoses<sup>[13]</sup>. The patient-specific virtual hyperemic flow was  
17  
18 used to compute CT-QFR value at every position of the reconstructed coronary tree.  
19  
20 A recent retrospective and observational study with 156 vessels from 134 patients  
21  
22 demonstrated good correlation ( $r = 0.79$ ;  $p < 0.001$ ) and agreement ( $0.00 \pm 0.06$ ;  $p =$   
23  
24  $0.823$ ) between CT-QFR and wire-based FFR, with a vessel-level diagnostic  
25  
26 concordance of 87%<sup>[14]</sup>. The average analysis time for CT-QFR was reported as less  
27  
28 than 20 minutes, with CT-QFR pullback curve computed in less than 20 seconds<sup>[14]</sup>.  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 A recent upgrade in the CT-QFR algorithm integrated deep learning technique  
39  
40 into coronary segmentation method thus improving the accuracy of automatic lumen  
41  
42 delineation and reducing the analysis time to less than 5 minutes per patient on an  
43  
44 off-the-shelf workstation. The incorporation of deep learning technique in CT-QFR  
45  
46 algorithm had the potential to improve the calculation efficiency significantly.  
47  
48 Large-scale studies have shown that the application of CT-FFR can reduce  
49  
50 unnecessary invasive coronary angiography. At the same time, it brings higher health  
51  
52 and economic benefits<sup>[23, 26]</sup>. The one-year follow-up of the ADVANCE study showed  
53  
54 that the MACE of patients with a CT-FFR value  $\leq 0.8$  was significantly higher than  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 that of patients with a CT-FFR value  $> 0.8$ <sup>[27]</sup>. Therefore, a kind of strategy pertaining  
5  
6 more to a rapid diagnosis, reduced invasive strategy, and lower costs is particularly  
7  
8 important. This study will prospectively validate the diagnostic efficacy of such a  
9  
10 faster computational approach to derive FFR from coronary CT angiography with can  
11  
12 be onsite for the first time.  
13  
14  
15

16  
17 Furthermore, severe calcification will affect the diagnosis of lesions on CT  
18  
19 images. It was proved that the presence of extensively calcified lesions influenced the  
20  
21 diagnostic accuracy and analysis variability<sup>[14]</sup>. Therefore, we intend to avoid the  
22  
23 effects of severe calcification so as to define whether CT-QFR is equivalent to QFR.  
24  
25 It's also the first time to compare the diagnostic performance of CCTA-derived QFR  
26  
27 with angiography-derived QFR. Therefore, the major secondary endpoint was  
28  
29 intended to investigate the non-inferiority of CT-QFR compared with QFR in the  
30  
31 patients without extensively calcified lesions.  
32  
33  
34  
35  
36  
37

38 This study will lay the foundation for future studies to look at the potential value  
39  
40 of CT-QFR technology in patients management. If the study achieves the expected  
41  
42 objectives, outpatients can receive coronary artery functional evaluation while  
43  
44 undergoing CCTA Examination. It can greatly reduce unnecessary invasive coronary  
45  
46 angiography and coronary interventions.  
47  
48  
49  
50  
51  
52

### 53 **Acknowledgements**

54  
55 We thank the colleagues in the departments participating into this study.  
56  
57

### 58 **Funding resources:**

1  
2  
3  
4 Funding: CAREER Study is an investigator-initiated clinical trial with external  
5  
6 funding from Clinical Research Plan of SHDC (No. SHDC2020CR3024B) issued by  
7  
8 Shanghai Hospital Development Center, Research Fund of Huadong Hospital (No.  
9  
10 2019lc015) and a Center of Geriatric Coronary Artery Disease.  
11  
12

### 13 14 **Author Contributions**

15  
16 Xinkai Qu and Shenxian Tu participated in study design, statistical hypotheses and  
17  
18 sample size calculation. Tingwen Weng and Qian Gan participated in manuscript  
19  
20 preparation, sample size calculation and writing the protocol of FFR measurement.  
21  
22 Zehang Li was involved in manuscript preparation, writing the protocol of QFR  
23  
24 computation and CT-QFR computation. Xinrong Zhai was involved in writing the  
25  
26 protocol of FFR measurement. Ming Li, Lin Qi and Cheng Li participated in writing  
27  
28 the protocol of CCTA Analysis. Shaofeng Guan, Wenzheng Han, Yang Chen, Liang  
29  
30 Zhang, Xifeng Chang was involved in writing the protocol of coronary angiography.  
31  
32  
33  
34  
35  
36

### 37 38 **Compliance with ethical standards**

39  
40 This research will not increase the risk and economic burden of patients; the patients'  
41  
42 rights will be fully protected. The study is conducted in accordance with the ethical  
43  
44 principles of the Declaration of Helsinki. The study protocol was approved by the  
45  
46 Ethics Committee of Huadong Hospital Affiliated to Fudan University.  
47  
48  
49

### 50 51 **Conflict of interest**

52  
53 The authors declare that they have no conflict of interest.  
54  
55

### 56 57 **Data Availability Statement**

58  
59 The data will be available from the corresponding author upon the reasonable request.  
60

## Patient and Public Involvement

Patients or the public will be involved in the design, or conduct, or reporting, or dissemination plans of our research.

## References

[1] Miller J M, Rochitte C E, Dewey M, et al. Diagnostic performance of coronary angiography by 64-row CT[J]. *N Engl J Med*,2008,359(22):2324-2336.

[2] Shaw L J, Berman D S, Maron D J, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy[J]. *Circulation*,2008,117(10):1283-1291.

[3] Kern M J, Samady H. Current concepts of integrated coronary physiology in the catheterization laboratory[J]. *J Am Coll Cardiol*,2010,55(3):173-185.

[4] Tonino P A, Fearon W F, De Bruyne B, et al. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation[J]. *J Am Coll Cardiol*,2010,55(25):2816-2821.

[5] Tonino P A, De Bruyne B, Pijls N H, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention[J]. *N Engl J Med*,2009,360(3):213-224.

1  
2  
3  
4 [6] De Bruyne B, Pijls N H, Bartunek J, et al. Fractional flow reserve in patients with  
5  
6 prior myocardial infarction[J]. *Circulation*,2001,104(2):157-162.  
7

8  
9 [7] Xaplanteris P, Fournier S, Pijls N, et al. Five-Year Outcomes with PCI Guided  
10  
11 by Fractional Flow Reserve[J]. *N Engl J Med*,2018,379(3):250-259.  
12

13  
14 [8] Neumann F J, Sousa-Uva M, Ahlsson A, et al. [2018 ESC/EACTS Guidelines on  
15  
16 myocardial revascularization. The Task Force on myocardial revascularization of  
17  
18 the European Society of Cardiology (ESC) and European Association for  
19  
20 Cardio-Thoracic Surgery (EACTS)][J]. *G Ital Cardiol (Rome)*,2019,20(7-8 Suppl  
21  
22 1):1S-61S.  
23  
24  
25

26  
27 [9] Tu S, Westra J, Yang J, et al. Diagnostic Accuracy of Fast Computational  
28  
29 Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary  
30  
31 Angiography: The International Multicenter FAVOR Pilot Study[J]. *JACC*  
32  
33 *Cardiovasc Interv*,2016,9(19):2024-2035.  
34  
35  
36

37  
38 [10] Xu B, Tu S, Qiao S, et al. Diagnostic Accuracy of Angiography-Based  
39  
40 Quantitative Flow Ratio Measurements for Online Assessment of Coronary  
41  
42 Stenosis[J]. *J Am Coll Cardiol*,2017,70(25):3077-3087.  
43  
44

45  
46 [11] Westra J, Andersen B K, Campo G, et al. Diagnostic Performance of  
47  
48 In-Procedure Angiography-Derived Quantitative Flow Reserve Compared to  
49  
50 Pressure-Derived Fractional Flow Reserve: The FAVOR II Europe-Japan Study[J].  
51  
52 *J Am Heart Assoc*,2018,7(14).  
53  
54

55  
56 [12] Westra J, Tu S, Winther S, et al. Evaluation of Coronary Artery Stenosis by  
57  
58 Quantitative Flow Ratio During Invasive Coronary Angiography: The WIFI II  
59  
60

1  
2  
3  
4 Study (Wire-Free Functional Imaging II)[J]. Circ Cardiovasc  
5  
6 Imaging,2018,11(3):e7107.  
7

8  
9 [13] Westra J, Tu S, Campo G, et al. Diagnostic performance of quantitative flow  
10 ratio in prospectively enrolled patients: An individual patient-data meta-analysis[J].  
11 Catheter Cardiovasc Interv,2019,94(5):693-701.  
12  
13  
14

15  
16 [14] Li Z, Zhang J, Xu L, et al. Diagnostic Accuracy of a Fast Computational  
17 Approach to Derive Fractional Flow Reserve From Coronary CT Angiography[J].  
18 JACC Cardiovasc Imaging,2020,13(1 Pt 1):172-175.  
19  
20  
21

22  
23 [15] Min J K, Berman D S, Budoff M J, et al. Rationale and design of the DeFACTO  
24 (Determination of Fractional Flow Reserve by Anatomic Computed Tomographic  
25 Angiography) study[J]. J Cardiovasc Comput Tomogr,2011,5(5):301-309.  
26  
27  
28

29  
30 [16] Leipsic J, Abbara S, Achenbach S, et al. SCCT guidelines for the interpretation  
31 and reporting of coronary CT angiography: a report of the Society of Cardiovascular  
32 Computed Tomography Guidelines Committee[J]. J Cardiovasc Comput  
33 Tomogr,2014,8(5):342-358.  
34  
35  
36  
37

38  
39 [17] Tu S, Ding D, Chang Y, et al. Diagnostic accuracy of quantitative flow ratio for  
40 assessment of coronary stenosis significance from a single angiographic view: A  
41 novel method based on bifurcation fractal law[J]. Catheter Cardiovasc Interv,2021.  
42  
43  
44  
45

46  
47 [18] Corcoran D, Hennigan B, Berry C. Fractional flow reserve: a clinical  
48 perspective[J]. Int J Cardiovasc Imaging,2017,33(7):961-974.  
49  
50  
51

52  
53 [19] Taylor C A, Fonte T A, Min J K. Computational fluid dynamics applied to  
54 cardiac computed tomography for noninvasive quantification of fractional flow  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 reserve: scientific basis[J]. *J Am Coll Cardiol*,2013,61(22):2233-2241.

5  
6 [20] Koo B K, Erglis A, Doh J H, et al. Diagnosis of ischemia-causing coronary  
7  
8 stenoses by noninvasive fractional flow reserve computed from coronary computed  
9  
10 tomographic angiograms. Results from the prospective multicenter  
11  
12 DISCOVER-FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via  
13  
14 Noninvasive Fractional Flow Reserve) study[J]. *J Am Coll*  
15  
16 *Cardiol*,2011,58(19):1989-1997.

17  
18 [21] Nakazato R, Park H B, Berman D S, et al. Noninvasive fractional flow reserve  
19  
20 derived from computed tomography angiography for coronary lesions of  
21  
22 intermediate stenosis severity: results from the DeFACTO study[J]. *Circ Cardiovasc*  
23  
24 *Imaging*,2013,6(6):881-889.

25  
26 [22] Nørgaard B L, Leipsic J, Gaur S, et al. Diagnostic performance of noninvasive  
27  
28 fractional flow reserve derived from coronary computed tomography angiography in  
29  
30 suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow  
31  
32 Using CT Angiography: Next Steps)[J]. *J Am Coll Cardiol*,2014,63(12):1145-1155.

33  
34 [23] Douglas P S, Pontone G, Hlatky M A, et al. Clinical outcomes of fractional flow  
35  
36 reserve by computed tomographic angiography-guided diagnostic strategies vs.  
37  
38 usual care in patients with suspected coronary artery disease: the prospective  
39  
40 longitudinal trial of FFR(CT): outcome and resource impacts study[J]. *Eur Heart*  
41  
42 *J*,2015,36(47):3359-3367.

43  
44 [24] Lu M T, Ferencik M, Roberts R S, et al. Noninvasive FFR Derived From  
45  
46 Coronary CT Angiography: Management and Outcomes in the PROMISE Trial[J].  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 JACC Cardiovasc Imaging,2017,10(11):1350-1358.

5  
6 [25] Nørgaard B L, Leipsic J, Koo B K, et al. Coronary Computed Tomography  
7  
8 Angiography Derived Fractional Flow Reserve and Plaque Stress[J]. Curr  
9  
10 Cardiovasc Imaging Rep,2016,9:2.  
11

12  
13 [26] Hlatky M A, De Bruyne B, Pontone G, et al. Quality-of-Life and Economic  
14  
15 Outcomes of Assessing Fractional Flow Reserve With Computed Tomography  
16  
17 Angiography: PLATFORM[J]. J Am Coll Cardiol,2015,66(21):2315-2323.  
18  
19


20  
21 [27] Patel M R, Nørgaard B L, Fairbairn T A, et al. 1-Year Impact on Medical  
22  
23 Practice and Clinical Outcomes of FFR(CT): The ADVANCE Registry[J]. JACC  
24  
25 Cardiovasc Imaging,2020,13(1 Pt 1):97-105.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 **Figure legend:**

39  
40 Figure 1. Study flowchart. CCTA, Coronary computed tomography angiography;  
41  
42 FFR, fractional flow reserve; QFR, Quantitative flow ratio; CT-QFR, CCTA-derived  
43  
44 Quantitative Flow Ratio.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




338x190mm (96 x 96 DPI)

Section & Topic	No	Item	Reported on page #
<b>TITLE OR ABSTRACT</b>			
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy: Diagnostic Accuracy of CCTA-derived versus Angiography-derived Quantitative Flow Ratio (CAREER) Study: Rationale and Design	Page 1
<b>ABSTRACT</b>			
	2	Structured summary of study design, methods, results, and conclusions : Background: Coronary computed tomography angiography (CCTA)- derived quantitative flow ratio (CT-QFR) is a novel non-invasive technology to assess the physiological significance of coronary stenoses, which enables fast and onsite computation of fractional flow reserve (FFR) from CCTA images. The objective of this investigator-initiated, prospective, single-center clinical trial is to evaluate the diagnostic performance of CT-QFR with respect to angiography-derived QFR, using FFR as the reference standard. Methods: A total of 216 patients who have at least 1 lesion with a diameter stenosis of 30% to 90% in an artery with $\geq 2.0$ mm reference diameter will be enrolled in the study. FFR will be measured during invasive coronary angiography. CT-QFR, and QFR will be assessed in two independent core laboratories in blinded fashion. The primary endpoint is the diagnostic accuracy of CT-QFR in identifying hemodynamically significant coronary stenosis with FFR as the reference standard. Major secondary endpoint is the non-inferiority of CT-QFR compared with QFR in the patients without extensively calcified lesions. Discussion: This study will be the first study to prospectively validate the diagnostic accuracy of CT-QFR compared with QFR, using FFR as the reference standard.	Page 3
<b>INTRODUCTION</b>			
	3	Scientific and clinical background, including the intended use and clinical role of the index test : Coronary computed tomography angiography (CCTA) is a non-invasive test that enables visualization of coronary anatomy and the characteristics of arterial plaques with high sensitivity and negative predictive value. However, conventional CCTA does not allow for physiological assessment of coronary stenosis. Fractional flow reserve (FFR) is the current gold standard for evaluating the physiological significance of coronary stenosis in the catheterization laboratory. An FFR-guided revascularization strategy was validated with improved clinical outcomes and cost-effectiveness compared to a traditional invasive coronary angiography-guided strategy. The use of FFR is supported by both European guidelines (Class I, Level of Evidence: A) and American guidelines (Class IIa, Level of Evidence: A) in assessing coronary stenosis and to guide revascularization. However, the adoption of FFR was limited due to prolonged procedural time, increased cost, patient discomfort, and operator's confidence in visual assessment from coronary angiograms. Several computational FFR methods were developed to overcome the above limitations. Quantitative flow ratio (QFR), a new method for fast computation of FFR based on invasive coronary angiography (ICA) and empirical fluid dynamic equations was recently developed. The overall diagnostic concordance between QFR and FFR was reported as 87% in a recent meta-analysis of prospective clinical studies. More recently, CCTA-derived QFR, namely CT-QFR, has been developed as a method for fast computation of FFR from CCTA images based on previously validated QFR algorithm. A recent retrospective and observational study demonstrated a good diagnostic concordance of 87%. In addition, its analysis time has been reduced to less than 5 minutes per patient on an off-the-shelf workstation. The diagnostic accuracy of this CT-QFR software version for on-site evaluation of coronary stenosis severity remains unknown. Furthermore, the difference in the diagnostic performance of QFR when applied to non-invasive CCTA images and to ICA has not been studied. We are therefore planning to prospectively validate the diagnostic performance of on-site CT-QFR analysis compared with QFR, using FFR as the reference standard.	Page 4, 5
	4	Study objectives and hypotheses: The primary endpoint of the study is the patient-level diagnostic accuracy of on-site CT-QFR in identifying physiologically significant coronary artery stenosis, using FFR as the reference standard. Major secondary endpoint is the non-inferiority of CT-QFR compared with QFR in the vessels without extensively calcified lesions defined by the combination of a cross-sectional calcium arc $>90^\circ$ and a thickness $>1.5$ mm. Other secondary objectives of the study will include the following. (1) Other common measures of diagnostic performance of CT-QFR, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) at the patient level compared with FFR as the reference standard. (2) Correlation between CT-QFR and FFR. (3) The comparison of the discrimination ability between CT-QFR, CCTA-derived percent	Page 5,6

		diameter stenosis (CTA-DS%), and QCA-derived DS% for identifying physiologically significant stenosis with FFR as the reference standard.	
<b>METHODS</b>			
<i>Study design</i>	<b>5</b>	Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study): This study is an investigator-initiated, prospective, single-center clinical trial to validate the diagnostic performance of on-site CT-QFR using FFR as the reference standard. The study is conducted in accordance with the ethical principles of the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Huadong Hospital Affiliated to Fudan University. Before the study starts, written informed consent form will be obtained from patients willing to participate in the study and approved by the institutional review board/independent ethics committee of Huadong Hospital Affiliated to Fudan University.	Page 5
<i>Participants</i>	<b>6</b>	Eligibility criteria : Inclusion criteria are: (1) at least 1 lesion with DS% between 30% and 90% in a coronary artery with a $\geq 2.0$ mm reference vessel diameter by visual estimation; (2) invasive coronary angiography performed less than 30 days after CCTA; (3) age over 35 years but less than or equal to 85 years. Exclusion criteria are: (1) prior percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) of the interrogated lesion; (2) myocardial bridge involved in the interrogated vessel; (3) presence of collateral flow; (4) severe heart failure (NYHA $\geq$ III); (5) known severe renal failure (eGFR $<$ 30 ml/min/1.73m <sup>2</sup> ); (6) contraindicated to use contrast agents, beta blockers, nitrates or adenosine drugs; (7) Recent prior myocardial infarction within 1 month of CCTA; (8) low image quality CCTA or coronary angiography to be assessed such as motion artifacts, poor filling of contrast agent, etc.; (9) any factors that affect the image quality of CCTA and coronary angiography, such as frequent premature contractions, atrial fibrillation, etc.	Page 5, 6
	<b>7</b>	Potentially eligible participants will be identified on their symptoms and results from previous tests.	Page 5
	<b>8</b>	Where and when potentially eligible participants were identified (setting, location and dates): Recruitment has been ongoing at Huadong Hospital Affiliated to Fudan University, Shanghai, China since December 2020.	Page 5,6
	<b>9</b>	Participants formed a consecutive, convenience series.	Page 5
<i>Test methods</i>	<b>10a</b>	Index test: Coronary computed tomography angiography - derived quantitative flow ratio (CT-QFR); Angiography-derived quantitative flow ratio (QFR)	Page 4, 5
	<b>10b</b>	Reference standard: Fractional flow reserve (FFR).	Page 4, 5
	<b>11</b>	Rationale for choosing the reference standard: Fractional flow reserve (FFR) is the current gold standard for evaluating the physiological significance of coronary stenosis in the catheterization laboratory. An FFR-guided revascularization strategy was validated with improved clinical outcomes and cost-effectiveness compared to a traditional invasive coronary angiography-guided strategy.	Page 4
	<b>12a</b>	Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory : The performances of QFR $\leq$ 0.80 and CT-QFR $\leq$ 0.80 predict hemodynamically significant coronary stenosis.	Page11
	<b>12b</b>	Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory: The performance of FFR $\leq$ 0.80 predicts hemodynamically significant coronary stenosis.	Page11
	<b>13a</b>	Clinical information and reference standard results will not be available to the performers/readers of the index test.	Page 7-10
	<b>13b</b>	Clinical information and index test results will not be available to the assessors of the reference standard.	Page 7-10
<i>Analysis</i>	<b>14</b>	Methods for estimating or comparing measures of diagnostic accuracy : The performance of QFR $\leq$ 0.80 and CT-QFR $\leq$ 0.80 for predicting FFR $\leq$ 0.80 will be assessed by using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (+LR), negative likelihood ratio (-LR), and diagnostic accuracy, together with their 95% confidence intervals (CIs). The ROC curve analysis will be performed to assess area under the curve (AUC) of CT-QFR, QFR, CT-derived %DS and QCA derived %DS for predicting	Page 7-10

1		FFR≤0.80. The ROC curves will be compared by using the DeLong method. A two-side p value <0.05 is considered to indicate statistical significance.	
2			
3	15	How indeterminate index test or reference standard results were handled: When calculating the sample size, the data that could not be completed was included as the dropout rate, which accounted for 15%.	Page 7,8
4			
5			
6	16	How missing data on the index test and reference standard were handled: When calculating the sample size, the data that could not be completed was included as the dropout rate, which accounted for 15%.	Page 7,8
7			
8			
9	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory: Agreements between QFR, CT-QFR, and FFR will be assessed by Bland-Altman plot. The Bland-Altman plot depicts the differences of each pair of measurements versus their mean values with reference lines for the mean difference of all paired measurements. The limits of agreement are defined as mean±1.96 SD of absolute difference	Page 11,12
10			
11			
12			
13			
14			
15			
16	18	Intended sample size and how it was determined: The primary endpoint is the diagnostic accuracy of CT-QFR≤0.8 to identify hemodynamically significant coronary stenosis with FFR≤0.8 as the reference standard. The trial is powered for testing significance of the primary endpoint. The primary null and alternative hypotheses to be tested are H0, diagnostic accuracy of CT-QFR≤0.72, and H1, diagnostic accuracy of CT-QFR > 0.72. Estimates for the sample size calculation are based on the results from the retrospective study of CT-QFR[14], where an accuracy of 87% at patient level was found. In this prospective study, the accuracy is conservatively estimated as 82% for consecutively enrolled patient population, and with a target value set as 72%, which is chosen to be higher than the one in the DeFACTO study[15].The sample size is analysed for paired proportions using the following formula: $N = \frac{[Z_{1-\alpha/2}\sqrt{P_0(1-P_0)} + Z_{1-\beta}\sqrt{P_T(1-P_T)}]^2}{(P_T - P_0)^2}$ With power = 0.90, two-tailed alpha = 0.05, a total of 188 patients with paired CT-QFR and FFR are required to reject the null hypothesis for diagnostic accuracy. To account for incomplete CT-QFR/CT-DS%/FFR/QFR/QCA data of 15% at most, a total of 216 patients need to be enrolled. The major secondary endpoint is to validate the non-inferiority of CT-QFR compared with QFR in the patients without extensively calcified lesions. Analyzed by the enrollment of 216 patients, about 158 patients will be calculated according to the proportion, 26.9%, of extensively calcified lesions from the retrospective study[14]. It will be tested for the capability in achieving the major secondary endpoint. The accuracy of 89.5% for CT-QFR in non-severe calcified lesions[14] and the accuracy of 92.7% for QFR[10] are used to calculate the sample size. We set the non-inferiority threshold as 15%. It will be analyzed by the following formula: $N_T = \frac{(Z_{1-\alpha/2} + Z_{1-\beta})^2 [P_C(1 - P_C) + P_T(1 - P_T)]}{(D - \Delta)^2}$ With power = 0.90, two-tailed alpha = 0.05, a total of 122 patients are required to validate the non-inferiority. To account for incomplete CT-QFR/CTA-DS%/FFR/QFR/QCA data of 15% at most , 141 patients need to be enrolled. Therefore, 158 patients without extensively calcified lesions meet the sample size of the major secondary endpoint. Therefore, the sample size is set as 216 patients to satisfy the requirements for validating both primary and major secondary endpoints.	Page 7,8
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45	<b>RESULTS</b>		
46	<i>Participants</i>	19 Flow of participants, using a diagram:	Page 11
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

	<b>20</b>	Baseline demographic and clinical characteristics of participants: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	<b>21a</b>	Distribution of severity of disease in those with the target condition: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	<b>21b</b>	Distribution of alternative diagnoses in those without the target condition: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	<b>22</b>	Time interval and any clinical interventions between index test and reference standard: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
<i>Test results</i>	<b>23</b>	Cross tabulation of the index test results (or their distribution) by the results of the reference standard: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	<b>24</b>	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals): This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	<b>25</b>	Any adverse events from performing the index test or the reference standard: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
<i>DISCUSSION</i>	<b>26</b>	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	<b>27</b>	Implications for practice, including the intended use and clinical role of the index test: This study will prospectively validate the diagnostic efficacy of a fast computational approach to derive FFR from coronary CT angiography with can be onsite for the first time. Furthermore, severe calcification will affect the diagnosis of lesions on CT images. It was proved that the presence of extensively calcified lesions influenced the diagnostic accuracy and analysis For peer review only - <a href="http://bmjopen.bmj.com/site/about/guidelines.xhtml">http://bmjopen.bmj.com/site/about/guidelines.xhtml</a>



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

variability. Therefore, we intend to avoid the effects of severe calcification so as to define whether CT-QFR is equivalent to QFR. It's also the first time to compare the diagnostic performance of CCTA-derived QFR with angiography-derived QFR.

This study will lay the foundation for future studies to look at the potential value of CT-QFR technology in patients management. If the study achieves the expected objectives, outpatients can receive coronary artery functional evaluation while undergoing CCTA Examination. It can greatly reduce unnecessary invasive coronary angiography and coronary interventions.

**OTHER INFORMATION**

28	Registration number and name of registry: ClinicalTrials.gov Identifier: NCT04665817	Page 5
29	Where the full study protocol can be accessed: This is the protocol manuscript.	
30	Sources of funding and other support; role of funders: CAREER Study is an investigator-initiated clinical trial with external funding from Clinical Research Plan of SHDC (No. SHDC2020CR3024B) issued by Shanghai Hospital Development Center, Research Fund of Huadong Hospital (No. 2019lc015) and a Center of Geratic Coronary Artery Disease.	Page 15



# STARD 2015

---

## AIM

STARD stands for “Standards for Reporting Diagnostic accuracy studies”. This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.

---

## EXPLANATION

A **diagnostic accuracy study** evaluates the ability of one or more medical tests to correctly classify study participants as having **atarget condition**. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.

The test whose accuracy is evaluated is called **index test**. A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the **reference standard**. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.

If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the **sensitivity** of the index test (the proportion of participants *with* the target condition who have a positive index test), and its **specificity** (the proportion *without* the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or “2x2” table), several other accuracy statistics can be estimated, such as the positive and negative **predictive values** of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical **precision** of the measurements.

If the index test results can take more than two values, categorization of test results as positive or negative requires a **test positivity cut-off**. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The **area under the ROC curve** informs in a single numerical value about the overall diagnostic accuracy of the index test.

The **intended use** of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The **clinical role** of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.

Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.

---

## DEVELOPMENT

This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.

More information can be found on <http://www.equator-network.org/reporting-guidelines/stard>.



# BMJ Open

## Diagnostic Accuracy of CCTA-derived versus Angiography-derived Quantitative Flow Ratio (CAREER) Study: A prospective study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055481.R1
Article Type:	Protocol
Date Submitted by the Author:	28-Dec-2021
Complete List of Authors:	Weng, Tingwen; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Gan, Qian; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Li, Zehang; Shanghai Jiao Tong University, School of Biomedical Engineering Guan, Shaofeng; Huadong Hospital Affiliated to Fudan University Han, Wenzheng; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Zhai, Xinrong; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Li, Ming; Huadong Hospital Affiliated to Fudan University, Department of Radiology Qi, Lin; Huadong Hospital Affiliated to Fudan University, Department of Radiology Li, Cheng; Huadong Hospital Affiliated to Fudan University, Department of Radiology Chen, Yang; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Zhang, Liang; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Chang, Xifeng; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Tu, Shengxian; Shanghai Jiao Tong University QU, XINKAI; Huadong Hospital Affiliated to Fudan University, Department of Cardiology
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Diagnostics
Keywords:	Adult cardiology < CARDIOLOGY, Coronary heart disease < CARDIOLOGY, Coronary intervention < CARDIOLOGY, Cardiomyopathy < CARDIOLOGY, Ischaemic heart disease < CARDIOLOGY





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open: first published as 10.1136/bmjopen-2021-055481 on 23 June 2022. Downloaded from <http://bmjopen.bmj.com/> on August 5, 2024 by guest. Protected by copyright.

1 **Title: Diagnostic Accuracy of CCTA-derived versus Angiography-derived**  
2 **Quantitative Flow Ratio (CAREER) Study: A prospective study protocol**

3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15 Running title: The research protocol of the CAREER study  
16  
17  
18  
19

20 Tingwen Weng,<sup>a\*</sup>MD., Qian Gan, <sup>a\*</sup>MD. PhD., Zehang Li, <sup>b</sup>BSc., Shaofeng Guan,  
21  
22 <sup>a</sup>MD.PhD., Wenzheng Han, <sup>a</sup>MD.PhD., Xinrong Zhai, <sup>a</sup>MD., Ming Li, <sup>c</sup>MD.PhD., Lin  
23  
24 Qi, <sup>c</sup>MD., Cheng Li, <sup>c</sup>MD., Yang Chen, <sup>a</sup>MD., Liang Zhang, <sup>a</sup>MD., Xifeng Chang, <sup>a</sup>  
25  
26 MD., Shengxian Tu, <sup>b</sup>PhD., Xinkai Qu <sup>a</sup>MD.PhD.  
27  
28  
29  
30  
31  
32  
33  
34

35 a Department of Cardiology, Huadong Hospital Affiliated to Fudan University,  
36  
37 Shanghai, China,  
38

39  
40 b Biomedical Instrument Institute, School of Biomedical Engineering, Shanghai Jiao  
41  
42 Tong University, Shanghai, China,  
43  
44

45 c Department of Radiology, Huadong Hospital Affiliated to Fudan University,  
46  
47 Shanghai, China.  
48  
49

50  
51  
52  
53 \*Equal contributors. Tingwen Weng and Qian Gan contributed equally to this work.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **1 Corresponding author:**  
5

6 2 Xinkai Qu MD. PhD.  
7

8  
9 3 Huadong Hospital Affiliated to Fudan University  
10

11 4 221 Yan'an W Rd, Jing'an District, Shanghai, China, 200040  
12

13  
14 5 E-mail: [qxkhuadong@sina.com](mailto:qxkhuadong@sina.com) Phone: +86 13916320399  
15

16  
17 6 Shengxian Tu PhD.  
18

19 7 Biomedical Instrument Institute, School of Biomedical Engineering, Shanghai Jiao  
20

21  
22 8 Tong University, Shanghai, China,  
23

24  
25 9 E-mail: [sxtu@sjtu.edu.cn](mailto:sxtu@sjtu.edu.cn) Phone: +86 13681841194  
26

27 10  
28

29  
30 11  
31

32  
33 12  
34

35  
36 13  
37

38  
39 14  
40

41  
42 15  
43

44  
45 16  
46

47  
48 17  
49

50  
51 18  
52

53  
54 19  
55

56  
57 20  
58

59  
60 21  
61

62  
63 22  
64

## 1 **Abstract**

2 **Introduction:** Coronary computed tomography angiography (CCTA)-derived  
3 quantitative flow ratio (CT-QFR) is a novel non-invasive technology to assess the  
4 physiological significance of coronary stenoses, which enables fast and on site  
5 computation of fractional flow reserve (FFR) from CCTA images. The objective of this  
6 investigator-initiated, prospective, single-center clinical trial is to evaluate the  
7 diagnostic performance of CT-QFR with respect to angiography-derived QFR, using  
8 FFR as the reference standard.

9 **Methods and analysis:** A total of 216 patients who have at least 1 lesion with a  
10 diameter stenosis of 30% to 90% in an artery with  $\geq 2.0$ mm reference diameter will be  
11 enrolled in the study. FFR will be measured during invasive coronary angiography. CT-  
12 QFR, and QFR will be assessed in two independent core laboratories in blinded fashion.  
13 The primary endpoint is the diagnostic accuracy of CT-QFR in identifying  
14 hemodynamically significant coronary stenosis with FFR as the reference standard.  
15 Major secondary endpoint is the non-inferiority of CT-QFR compared with QFR in the  
16 patients without extensively calcified lesions.

17 **Ethic and Dissemination:** The study was approved by the Ethics Committee of  
18 Huadong Hospital Affiliated to Fudan University (2020K192). Outcomes will be  
19 disseminated through publications in peer-reviewed journals and presentations at  
20 scientific conferences.

## 21 **Article summary**

## 22 **Strengths and limitations of this study:**

- 1  
2  
3  
4 1 ➤ This study is the first prospective clinical trial to validate the diagnostic  
5  
6 2 performance of on-site CT-QFR using FFR as the reference standard.  
7  
8  
9 3 ➤ This study will lay the foundation for future studies to look at the potential value  
10  
11 4 of CT-QFR technology in patients management.  
12  
13  
14 5 ➤ It's the first time to explore the difference in the diagnostic performance of QFR  
15  
16 6 technology when applied to noninvasive CCTA images and to ICA.  
17  
18  
19 7 ➤ CT-QFR and QFR will be computed in blinded fashion and compared with FFR.  
20  
21  
22 8 ➤ Unfortunately, due to the tight schedule and insufficient funding, a multi-center  
23  
24 9 study cannot be conducted.  
25  
26  
27  
28  
29

30 11 **Key words:** Coronary computed tomography angiography- derived quantitative flow  
31  
32 12 ratio ( CT-QFR ) ; Angiography-derived quantitative flow ratio ( QFR ) ;  
33  
34 13 Diagnostic accuracy ; Non-inferiority  
35  
36  
37

38 14 **Trial registration:** ClinicalTrials.gov Identifier: NCT04665817  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 22 **Introduction**

1  
2  
3  
4 1 Coronary computed tomography angiography (CCTA) is a noninvasive test that  
5  
6 2 enables visualization of coronary anatomy and the characteristics of arterial plaques  
7  
8  
9 3 with high sensitivity and negative predictive value <sup>[1]</sup>. However, conventional CCTA  
10  
11 4 does not allow for physiological assessment of coronary stenosis<sup>[2]</sup>. Fractional flow  
12  
13  
14 5 reserve (FFR) is the current gold standard for evaluating the physiological significance  
15  
16  
17 6 of coronary stenosis in the catheterization laboratory <sup>[3]</sup>. An FFR-guided  
18  
19  
20 7 revascularization strategy was validated with improved clinical outcomes and cost-  
21  
22 8 effectiveness compared to a traditional invasive coronary angiography-guided strategy  
23  
24  
25 9 <sup>[4-7]</sup>. The use of FFR is supported by both European guidelines (Class I, Level of  
26  
27  
28 10 Evidence: A) and American guidelines (Class IIa, Level of Evidence: A) in assessing  
29  
30  
31 11 coronary stenosis and to guide revascularization<sup>[8]</sup>. However, the adoption of FFR was  
32  
33  
34 12 limited due to prolonged procedural time, increased cost, patient discomfort, and  
35  
36  
37 13 operator's confidence in visual assessment from coronary angiograms.

38 14 Several computational FFR methods were developed to overcome the above  
39  
40  
41 15 limitations. Quantitative flow ratio (QFR), a new method for fast computation of FFR  
42  
43  
44 16 based on invasive coronary angiography (ICA) and empirical fluid dynamic equations  
45  
46  
47 17 was recently developed<sup>[9]</sup>. The overall diagnostic concordance between QFR and FFR  
48  
49  
50 18 was reported as 87% in a recent meta-analysis of prospective clinical studies<sup>[10]</sup>.

51 19 More recently, CCTA-derived QFR, namely CT-QFR, has been developed as a  
52  
53  
54 20 method for fast computation of FFR from CCTA images based on previously validated  
55  
56  
57 21 QFR algorithm. A recent retrospective and observational study demonstrated a good  
58  
59  
60 22 diagnostic concordance of 87% <sup>[11]</sup>. In addition, its analysis time has been reduced to

1 less than 5 minutes per patient on an off-the-shelf work station. The diagnostic accuracy  
2 of this CT-QFR software version for on-site evaluation of coronary stenosis severity  
3 remains unknown. Furthermore, the differences in the diagnostic performance of QFR  
4 when applied to noninvasive CCTA images and to ICA have not been studied. We are  
5 therefore planning to prospectively validate the diagnostic performance of on-site CT-  
6 QFR analysis compared with QFR, using FFR as the reference standard.

## 8 **Methods and analysis**

### 9 **Study design**

10 This study is an investigator-initiated, prospective, single-center clinical trial to  
11 validate the diagnostic performance of on-site CT-QFR using FFR as the reference  
12 standard. The study is conducted in accordance with the ethical principles of the  
13 Declaration of Helsinki. The study protocol was approved by the Ethics Committee of  
14 Huadong Hospital Affiliated to Fudan University. Before the study starts, written  
15 informed consent form will be obtained from patients willing to participate in the study  
16 and approved by the institutional review board/independent ethics committee of  
17 Huadong Hospital Affiliated to Fudan University (2020K192). The protocol of the trial  
18 has been registered at <http://clinicaltrials.gov> (NCT04665817).

### 20 **Study objectives**

21 The primary endpoint of the study is the patient-level diagnostic accuracy of on-  
22 site CT-QFR in identifying physiologically significant coronary artery stenosis, using

1 FFR as the reference standard. Major secondary end point is the non-inferiority of CT-  
2 QFR compared with QFR in the vessels without extensively calcified lesions defined  
3 by the combination of a cross-sectional calcium arc  $>90^\circ$  and a thickness  $>1.5$  mm.  
4 Other secondary objectives of the study will include the following. (1) Other common  
5 measures of diagnostic performance of CT-QFR, including sensitivity, specificity,  
6 positive predictive value (PPV), and negative predictive value (NPV) at the patient level  
7 compared with FFR as the reference standard. (2) Correlation between CT-QFR and  
8 FFR. (3) The comparison of the discrimination ability between CT-QFR, CCTA-  
9 derived percent diameter stenosis (CTA-DS%), and QCA-derived DS% for identifying  
10 physiologically significant stenosis with FFR as the reference standard.

## 12 **Patient population**

13 Patients with stable or unstable angina pectoris or non-acute phase of myocardial  
14 infarction who are undergoing CCTA examination and scheduled for coronary  
15 angiography within 30 days will be screened. Inclusion criteria are: (1) at least 1 lesion  
16 with DS% between 30% and 90% in a coronary artery with a  $\geq 2.0$ mm reference vessel  
17 diameter by visual estimation; (2) invasive coronary angiography performed less than  
18 30 days after CCTA; (3) age over 35 years but less than or equal to 85 years. Exclusion  
19 criteria are: (1) prior percutaneous coronary intervention (PCI) or coronary artery  
20 bypass graft (CABG) of the interrogated lesion; (2) myocardial bridge involved in the  
21 interrogated vessel; (3) presence of collateral flow; (4) severe heart failure (NYHA  $\geq$ III);  
22 (5) known severe renal failure (eGFR  $< 30$  ml/min/1.73m<sup>2</sup>); (6) contraindicated to use



1 contrast agents, beta blockers, nitrates or adenosine drugs; (7) Recent prior myocardial  
 2 infarction within 1 month of CCTA; (8) low image quality CCTA or coronary  
 3 angiography to be assessed such as motion artifacts, poor filling of contrast agent, etc.;  
 4 (9) any factors that affect the image quality of CCTA and coronary angiography, such  
 5 as frequent premature contractions, atrial fibrillation, etc.

6

### 7 **Statistical hypotheses and Sample Size Calculation**

8 The primary endpoint is the diagnostic accuracy of CT-QFR $\leq$ 0.8 to identify  
 9 hemodynamically significant coronary stenosis with FFR $\leq$ 0.8 as the reference standard.

10 The trial is powered for testing significance of the primary endpoint. The primary null  
 11 and alternative hypotheses to be tested are H<sub>0</sub>, diagnostic accuracy of CT-QFR $\leq$ 0.72,  
 12 and H<sub>1</sub>, diagnostic accuracy of CT-QFR  $>$  0.72. Estimates for the sample size  
 13 calculation are based on the results from the retrospective study of CT-QFR<sup>[11]</sup>, where  
 14 an accuracy of 87% at patient level was found. In this prospective study, the accuracy  
 15 is conservatively estimated as 82% for consecutively enrolled patient population, and  
 16 with a target value set as 72%, which is chosen to be higher than the one in the  
 17 DeFACTO study<sup>[12]</sup>. The sample size is analysed for paired proportions using the  
 18 following formula:

$$19 \quad N = \frac{[Z_{1-\alpha/2}\sqrt{P_0(1-P_0)} + Z_{1-\beta}\sqrt{P_T(1-P_T)}]^2}{(P_T - P_0)^2}$$

20 With power = 0.90, two-tailed alpha = 0.05, a total of 188 patients with paired CT-QFR  
 21 and FFR are required to reject the null hypothesis for diagnostic accuracy. To account  
 22 for incomplete CT-QFR/CT-DS%/FFR/QFR/QCA data of 15% at most, a total of 216

1 patients need to be enrolled.

2 The major secondary endpoint is to validate the non-inferiority of CT-QFR compared  
3 with QFR in the patients without extensively calcified lesions. Analyzed by the  
4 enrollment of 216 patients, about 158 patients will be calculated according to the  
5 proportion, 26.9%, of extensively calcified lesions from the retrospective study<sup>[11]</sup>. It  
6 will be tested for the capability in achieving the major secondary endpoint. The  
7 accuracy of 89.5% for CT-QFR in non-severe calcified lesions<sup>[11]</sup> and the accuracy of  
8 92.7% for QFR<sup>[13]</sup> are used to calculate the sample size. We set the non-inferiority  
9 threshold as 15%. It will be analyzed by the following formula:

$$N_T = \frac{(Z_{1-\alpha/2} + Z_{1-\beta})^2 [P_C(1 - P_C) + P_T(1 - P_T)]}{(D - \Delta)^2}$$

11 With power = 0.90, two-tailed alpha = 0.05, a total of 122 patients are required to  
12 validate the non-inferiority. To account for incomplete CT-QFR/CTA-  
13 DS%/FFR/QFR/QCA data of 15% at most, 141 patients need to be enrolled. Therefore,  
14 158 patients without extensively calcified lesions meet the sample size of the major  
15 secondary endpoint. Therefore, the sample size is set as 216 patients to satisfy the  
16 requirements for validating both primary and major secondary endpoints.

### 18 CCTA and CTA-DS% Analysis

19 Coronary computed tomography angiography will be performed on a dual-source  
20 CT system (SOMATOM Drive; Siemens Healthineers, Erlangen, Germany) or a 256  
21 detector row scanners CT system (Revolution CT; GE Healthcare) with prospective or  
22 retrospective electrocardiographic gating in accordance with Society of Cardiovascular

1 Computed Tomography guidelines<sup>[14]</sup>. Image interpretation of CCTA will be conducted  
2 in blinded fashion by an experienced investigator. Images with coronary artery stenosis  
3 detected visually will be further analyzed (CtaPlus; version 1.0, Pulse Medical Imaging  
4 Technology, Shanghai, China). Coronary stenosis will be quantified by using the  
5 following parameters: (i) the minimal lumen area (MLA) and the minimal lumen  
6 diameter (MLD), and (ii) the percentage diameter stenosis (DS%) and the percentage  
7 area stenosis (AS%).

8

### 9 **CT- QFR Computation**

10 CT-QFR computation will be performed by experienced analysts using a recently  
11 developed software package (CtaPlus, version 1.0; Pulse Medical Imaging Technology,  
12 Shanghai, China), blinded to both QFR and FFR data. Detailed methodologies for CT-  
13 QFR computation have been published previously<sup>[11]</sup>. A recent upgrade in the CT-QFR  
14 algorithm integrated deep learning technique into coronary segmentation method to  
15 improve the computation efficiency. Manual corrections are allowed if the automated  
16 delineation lumen contour is sub-optimal, particularly at the segment with calcified  
17 plaques. All coronary artery segments with reference lumen diameter  $\geq 1.5$  mm are  
18 analyzed. Subsequently, all the delineated coronary branches are automatically merged  
19 for reconstruction of entire coronary tree, based on which the healthy reference lumen  
20 is also reconstructed. Finally, CT-QFR value at each position of the coronary tree is  
21 computed using the previous validated QFR algorithm<sup>[9, 15]</sup>.

22

## 1 **Coronary Angiography**

2 Coronary angiography will be performed by using a 5- or 6-F catheter with a  
3 transfemoral or transradial approach. All patients will receive intravenous injection of  
4 heparin 100 IU/kg before angiography. Contrast media (Omnipaque 350 injection, GE  
5 Healthcare, Shanghai, China) will be injected manually with a forceful and stable  
6 injection. Coronary angiograms will be obtained from standard series of 6 to 8  
7 projections for the left coronary artery and 2 or 3 projections for the right coronary  
8 artery by using a monoplane or biplane radiographic system (AXIOM Artis FC and  
9 Artis zee Biplane MN, Siemens) at 15 frames/s. All images will be digitally stored for  
10 analysis.

## 11 **FFR Measurement**

12 Intracoronary pressure will be measured by using a RadiAnalyzer Xpress  
13 instrument and Certus pressure wire (St. Jude Medical, Plymouth, Minnesota). The  
14 pressure guidewire will be introduced into the coronary artery and positioned distal to  
15 the coronary stenosis. The position of the sensor of the pressure guide wire will be  
16 recorded on cine fluorography. Hyperemia will be induced by adenosine-5'-  
17 triphosphate (ATP) infusion (160 µg/kg/minute) through an antecubital vein over a  
18 minimum of 2 minutes. During steady-state hyperemia, mean proximal aortic pressure,  
19 mean intracoronary pressure distal to the target stenosis will be measured. Subsequently,  
20 the pressure guide wire will be slowly pulled back from the most distal to the proximal  
21 part of the artery by manual procedure during steady-state maximal hyperemia. If the  
22

1 pressures are not equalized at the end of the pullback (i.e. the pressure drift  $|Pa-Pd| > 3$   
2 mmHg), the whole FFR measurements should be repeated from the beginning.

#### 4 **QCA Analysis and QFR Computation**

5 Quantitative coronary angiographic (QCA) analysis and QFR computation will be  
6 performed in blinded fashion by using the recently developed QFR analysis system  
7 (AngioPlus Core; Pulse Medical Imaging Technology, Shanghai, China). The  
8 computational methods were previously described<sup>[9, 15]</sup>. Same as CT-DS% analysis,  
9 QCA analysis includes following parameters: (i) MLA and MLD, and (ii) DS% and  
10 AS%. It will be analyzed by well-trained technicians who have successfully completed  
11 QFR training. Before QFR analysis, the technicians will be informed about the location  
12 where the operators measured FFR so that QFR could be measured at the same vessel  
13 site. The QFR measure will be performed on the system placed in the control room.  
14 The investigators will be blinded to the FFR results.

#### 15 **Study flowchart**

16 A study flowchart is shown in Figure 1.

#### 17 **Statistical Analysis**

18 Continuous variables are presented as mean $\pm$ SD, and categorical variables will be  
19 presented as counts and percentages. Sensitivity, specificity to predict functionally  
20 significant stenosis ( $FFR \leq 0.80$ ). The performance of  $QFR \leq 0.80$  and  $CT-QFR \leq 0.80$  for  
21 predicting  $FFR \leq 0.80$  will be assessed by using sensitivity, specificity, positive  
22 predictive value (PPV), negative predictive value (NPV), positive likelihood ratio

1 (+LR), negative likelihood ratio (-LR), and diagnostic accuracy, together with their 95%  
2 confidence intervals (CIs). Pearson correlation or Spearman's correlation will be used  
3 to quantify the correlations between QFR, CT-QFR, and FFR. Agreements between  
4 QFR, CT-QFR, and FFR will be assessed by Bland-Altman plot. The Bland-Altman  
5 plot depicts the differences of each pair of measurements versus their mean values with  
6 reference lines for the mean difference of all paired measurements. The limits of  
7 agreement will be defined as  $\text{mean} \pm 1.96 \text{ SD}$  of absolute difference. The ROC curve  
8 analysis will be performed to assess area under the curve (AUC) of CT-QFR, QFR, CT-  
9 derived %DS and QCA derived %DS for predicting  $\text{FFR} \leq 0.80$ . The ROC curves will  
10 be compared by using the DeLong method. A two-side p value  $< 0.05$  will be considered  
11 to indicate statistical significance.

## 12 **Current status**

13 The study has been approved by the Ethics Committee of Huadong Hospital  
14 Affiliated to Fudan University. Five analysts have successfully completed the  
15 International Course on Coronary Image Analysis and Computational Physiology  
16 which covers FFR, QFR and CT-QFR. All of them have obtained qualification  
17 certificates for relevant analysis. Recruitment is ongoing at Huadong Hospital  
18 Affiliated to Fudan University, Shanghai, China. At the time of submission of this  
19 manuscript, 35 participants have been recruited to the study.

## 21 **Discussion**

22 The CAREER study will for the first time prospectively evaluate the diagnostic

1 accuracy of on-site CT-QFR analysis in identifying patients with physiologically  
2 significant coronary stenosis. In addition, diagnostic performance of CCTA-based  
3 versus angiography-based QFR in vessels without significantly calcified lesions will be  
4 compared. The study findings will provide pivotal data to support the clinical  
5 applications of CT-QFR in management of CAD patients.

6 The previously presented FFR computation method derived from computed  
7 tomography (FFR<sub>CT</sub>), a non-invasive technology, is a computational fluid dynamics  
8 modeling technique that enables the calculation of FFR from a coronary computed  
9 tomographic angiographic dataset<sup>[16]</sup>. The diagnostic performance of FFR<sub>CT</sub> has been  
10 validated in several multi-center prospective clinical trials <sup>[17-19]</sup>. The application of  
11 FFR<sub>CT</sub> can reduce unnecessary invasive coronary angiography <sup>[20, 21]</sup>. However, it  
12 heavily relies on the quality of the underlying computational models and sophisticated  
13 boundary conditions and required a few hours for computation<sup>[19]</sup>. Moreover, severe  
14 calcified lesions might affect the calculation results of FFR<sub>CT</sub> <sup>[22]</sup>.

15 Recently, a novel technique for the rapid computation of FFR from radiographic  
16 coronary angiography, named QFR, was accomplished by estimating the pressure drop  
17 due to coronary stenosis according to coronary lumen morphology and virtual  
18 hyperemic flow derived from contrast frame count without use of pressure wire and  
19 drug-induced hyperemia<sup>[9]</sup>. The diagnostic performance of this minimally invasive  
20 technique has been validated by several studies<sup>[9, 13, 23, 24]</sup>. More recently, the novel QFR  
21 algorithm has been applied to CCTA-images, and CCTA-derived QFR (namely CT-  
22 QFR), has been derived as a non-invasive technology to assess the physiological

1 significance of coronary stenoses<sup>[10]</sup>. The patient-specific virtual hyperemic flow was  
2 used to compute CT-QFR value at every position of the reconstructed coronary tree. A  
3 recent retrospective and observational study with 156 vessels from 134 patients  
4 demonstrated good correlation ( $r = 0.79$ ;  $p < 0.001$ ) and agreement ( $0.00 \pm 0.06$ ;  $p =$   
5  $0.823$ ) between CT-QFR and wire-based FFR, with a vessel-level diagnostic  
6 concordance of 87%<sup>[11]</sup>. The average analysis time for CT-QFR was reported as less  
7 than 20 minutes, with CT-QFR pullback curve computed in less than 20 seconds<sup>[11]</sup>.

8 A recent upgrade in the CT-QFR algorithm integrated deep learning technique into  
9 coronary segmentation method thus improving the accuracy of automatic lumen  
10 delineation and reducing the analysis time to less than 5 minutes per patient on an off-  
11 the-shelf workstation. The incorporation of deep learning technique in CT-QFR  
12 algorithm had the potential to improve the calculation efficiency significantly. Large-  
13 scale studies have shown that the application of CT-FFR can reduce unnecessary  
14 invasive coronary angiography. At the same time, it brings higher health and economic  
15 benefits<sup>[20, 25]</sup>. The one-year follow-up of the ADVANCE study showed that the MACE  
16 of patients with a CT-FFR value  $\leq 0.8$  was significantly higher than that of patients  
17 with a CT-FFR value  $> 0.8$ <sup>[26]</sup>. Therefore, a kind of strategy pertaining more to a rapid  
18 diagnosis, reduced invasive strategy, and lower costs is particularly important. This  
19 study will prospectively validate the diagnostic efficacy of such a faster computational  
20 approach to derive FFR from coronary CT angiography with can be onsite for the first  
21 time.

22 Furthermore, severe calcification will affect the diagnosis of lesions on CT images.



1  
2  
3  
4 1 It was proved that the presence of extensively calcified lesions influenced the diagnostic  
5  
6 2 accuracy and analysis variability<sup>[11]</sup>. Therefore, we intend to avoid the effects of severe  
7  
8  
9 3 calcification so as to define whether CT-QFR is equivalent to QFR. It's also the first  
10  
11 4 time to compare the diagnostic performance of CCTA-derived QFR with angiography-  
12  
13  
14 5 derived QFR. Therefore, the major secondary endpoint was intended to investigate the  
15  
16  
17 6 non-inferiority of CT-QFR compared with QFR in the patients without extensively  
18  
19  
20 7 calcified lesions.

21  
22 8 This study will lay the foundation for future studies to look at the potential value  
23  
24 9 of CT-QFR technology in patients management. If the study achieves the expected  
25  
26  
27 10 objectives, outpatients can receive coronary artery functional evaluation while  
28  
29  
30 11 undergoing CCTA Examination. It can greatly reduce unnecessary invasive coronary  
31  
32  
33 12 angiography and coronary interventions.

### 34 35 13 **Ethics and dissemination**

36  
37  
38 14 This research will not increase the risk and economic burden of patients and the  
39  
40 15 patients' rights will be fully protected. The study is conducted in accordance with the  
41  
42  
43 16 ethical principles of the Declaration of Helsinki. The study protocol was approved by  
44  
45  
46 17 the Ethics Committee of Huadong Hospital Affiliated to Fudan University (ref. number  
47  
48  
49 18 2020K192). All patients will provide written informed consent. Results of this study  
50  
51  
52 19 are to be published in respected, peer-reviewed journals and findings presented at  
53  
54  
55 20 scientific conferences in the field of Cardiology.

### 56 57 58 21 **Acknowledgements**

1 We thank the colleagues in the departments participating into this study.

## 2 **Funding resources:**

3 Funding: CAREER Study is an investigator-initiated clinical trial with external funding  
4 from Clinical Research Plan of SHDC ( No. SHDC2020CR3024B ) issued by  
5 Shanghai Hospital Development Center, Research Fund of Huadong Hospital (No.  
6 2019lc015) and a Center of Geriatric Coronary Artery Disease.

## 7 **Author Contributions**

8 Xinkai Qu and Shenxian Tu participated in study design, statistical hypotheses and  
9 sample size calculation. Tingwen Weng and Qian Gan participated in manuscript  
10 preparation, sample size calculation and writing the protocol of FFR measurement.  
11 Zehang Li was involved in manuscript preparation, writing the protocol of QFR  
12 computation and CT-QFR computation. XinrongZhai was involved in writing the  
13 protocol of FFR measurement. Ming Li, Lin Qi and Cheng Li participated in writing  
14 the protocol of CCTA Analysis. Shaofeng Guan, Wenzheng Han, Yang Chen, Liang  
15 Zhang, Xifeng Chang was involved in writing the protocol of coronary angiography.

## 16 **Conflict of interest**

17 The authors declare that they have no conflict of interest.

## 18 **Data Availability Statement**

19 The data will be available from the corresponding author upon the reasonable request.

## 20 **Patient and Public Involvement**

21 Patients or the public will be involved in the design, or conduct, or reporting, or  
22 dissemination plans of our research.

1

2

3

4 **References**

5 [1] Miller J M, Rochitte C E, Dewey M, et al. Diagnostic performance of coronary  
6 angiography by 64-row CT[J]. N Engl J Med,2008,359(22):2324-2336.

7 [2] Shaw L J, Berman D S, Maron D J, et al. Optimal medical therapy with or without  
8 percutaneous coronary intervention to reduce ischemic burden: results from the  
9 Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation  
10 (COURAGE) trial nuclear substudy[J]. Circulation,2008,117(10):1283-1291.

11 [3] Kern M J, Samady H. Current concepts of integrated coronary physiology in the  
12 catheterization laboratory[J]. J Am Coll Cardiol,2010,55(3):173-185.

13 [4] Tonino P A, Fearon W F, De Bruyne B, et al. Angiographic versus functional  
14 severity of coronary artery stenoses in the FAME study fractional flow reserve versus  
15 angiography in multivessel evaluation[J]. J Am Coll Cardiol,2010,55(25):2816-2821.

16 [5] Tonino P A, De Bruyne B, Pijls N H, et al. Fractional flow reserve versus  
17 angiography for guiding percutaneous coronary intervention[J]. N Engl J  
18 Med,2009,360(3):213-224.

19 [6] De Bruyne B, Pijls N H, Bartunek J, et al. Fractional flow reserve in patients with  
20 prior myocardial infarction[J]. Circulation,2001,104(2):157-162.

21 [7] Xaplanteris P, Fournier S, Pijls N, et al. Five-Year Outcomes with PCI Guided by  
22 Fractional Flow Reserve[J]. N Engl J Med,2018,379(3):250-259.

- 1 [8] Neumann F J, Sousa-Uva M, Ahlsson A, et al. [2018 ESC/EACTS Guidelines on  
2 myocardial revascularization. The Task Force on myocardial revascularization of the  
3 European Society of Cardiology (ESC) and European Association for Cardio-  
4 Thoracic Surgery (EACTS)][J]. *G Ital Cardiol (Rome)*,2019,20(7-8 Suppl 1):1S-61S.
- 5 [9] Tu S, Westra J, Yang J, et al. Diagnostic Accuracy of Fast Computational  
6 Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary  
7 Angiography: The International Multicenter FAVOR Pilot Study[J]. *JACC*  
8 *Cardiovasc Interv*,2016,9(19):2024-2035.
- 9 [10] Westra J, Tu S, Campo G, et al. Diagnostic performance of quantitative flow ratio  
10 in prospectively enrolled patients: An individual patient-data meta-analysis[J].  
11 *Catheter Cardiovasc Interv*,2019,94(5):693-701.
- 12 [11] Li Z, Zhang J, Xu L, et al. Diagnostic Accuracy of a Fast Computational Approach  
13 to Derive Fractional Flow Reserve From Coronary CT Angiography[J]. *JACC*  
14 *Cardiovasc Imaging*,2020,13(1 Pt 1):172-175.
- 15 [12] Min J K, Berman D S, Budoff M J, et al. Rationale and design of the DeFACTO  
16 (Determination of Fractional Flow Reserve by Anatomic Computed Tomographic  
17 Angiography) study[J]. *J Cardiovasc Comput Tomogr*,2011,5(5):301-309.
- 18 [13] Xu B, Tu S, Qiao S, et al. Diagnostic Accuracy of Angiography-Based Quantitative  
19 Flow Ratio Measurements for Online Assessment of Coronary Stenosis[J]. *J Am Coll*  
20 *Cardiol*,2017,70(25):3077-3087.
- 21 [14] Leipsic J, Abbara S, Achenbach S, et al. SCCT guidelines for the interpretation  
22 and reporting of coronary CT angiography: a report of the Society of Cardiovascular

- 1  
2  
3  
4 1 Computed Tomography Guidelines Committee[J]. J Cardiovasc Comput  
5  
6 2 Tomogr,2014,8(5):342-358.  
7  
8  
9 3 [15] Tu S, Ding D, Chang Y, et al. Diagnostic accuracy of quantitative flow ratio for  
10  
11 4 assessment of coronary stenosis significance from a single angiographic view: A  
12  
13 5 novel method based on bifurcation fractal law[J]. Catheter Cardiovasc Interv,2021.  
14  
15  
16 6 [16] Taylor C A, Fonte T A, Min J K. Computational fluid dynamics applied to cardiac  
17  
18 7 computed tomography for noninvasive quantification of fractional flow reserve:  
19  
20 8 scientific basis[J]. J Am Coll Cardiol,2013,61(22):2233-2241.  
21  
22  
23 9 [17] Koo B K, Erglis A, Doh J H, et al. Diagnosis of ischemia-causing coronary  
24  
25 10 stenoses by noninvasive fractional flow reserve computed from coronary computed  
26  
27 11 tomographic angiograms. Results from the prospective multicenter DISCOVER-  
28  
29 12 FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive  
30  
31 13 Fractional Flow Reserve) study[J]. J Am Coll Cardiol,2011,58(19):1989-1997.  
32  
33  
34 14 [18] Nakazato R, Park H B, Berman D S, et al. Noninvasive fractional flow reserve  
35  
36 15 derived from computed tomography angiography for coronary lesions of intermediate  
37  
38 16 stenosis severity: results from the DeFACTO study[J]. Circ Cardiovasc  
39  
40 17 Imaging,2013,6(6):881-889.  
41  
42  
43 18 [19] Nørgaard B L, Leipsic J, Gaur S, et al. Diagnostic performance of noninvasive  
44  
45 19 fractional flow reserve derived from coronary computed tomography angiography in  
46  
47 20 suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow  
48  
49 21 Using CT Angiography: Next Steps)[J]. J Am Coll Cardiol,2014,63(12):1145-1155.  
50  
51  
52 22 [20] Douglas P S, Pontone G, Hlatky M A, et al. Clinical outcomes of fractional flow  
53  
54  
55  
56  
57  
58  
59  
60

1 reserve by computed tomographic angiography-guided diagnostic strategies vs. usual  
2 care in patients with suspected coronary artery disease: the prospective longitudinal  
3 trial of FFR(CT): outcome and resource impacts study[J]. Eur Heart  
4 J,2015,36(47):3359-3367.

5 [21] Lu M T, Ferencik M, Roberts R S, et al. Noninvasive FFR Derived From  
6 Coronary CT Angiography: Management and Outcomes in the PROMISE Trial[J].  
7 JACC Cardiovasc Imaging,2017,10(11):1350-1358.

8 [22] Nørgaard B L, Leipsic J, Koo B K, et al. Coronary Computed Tomography  
9 Angiography Derived Fractional Flow Reserve and Plaque Stress[J]. Curr Cardiovasc  
10 Imaging Rep,2016,9:2.

11 [23] Westra J, Andersen B K, Campo G, et al. Diagnostic Performance of In-Procedure  
12 Angiography-Derived Quantitative Flow Reserve Compared to Pressure-Derived  
13 Fractional Flow Reserve: The FAVOR II Europe-Japan Study[J]. J Am Heart  
14 Assoc,2018,7(14).

15 [24] Westra J, Tu S, Winther S, et al. Evaluation of Coronary Artery Stenosis by  
16 Quantitative Flow Ratio During Invasive Coronary Angiography: The WIFI II Study  
17 (Wire-Free Functional Imaging II)[J]. Circ Cardiovasc Imaging,2018,11(3):e7107.

18 [25] Hlatky M A, De Bruyne B, Pontone G, et al. Quality-of-Life and Economic  
19 Outcomes of Assessing Fractional Flow Reserve With Computed Tomography  
20 Angiography: PLATFORM[J]. J Am Coll Cardiol,2015,66(21):2315-2323.

21 [26] Patel M R, Nørgaard B L, Fairbairn T A, et al. 1-Year Impact on Medical Practice  
22 and Clinical Outcomes of FFR(CT): The ADVANCE Registry[J]. JACC Cardiovasc

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 Imaging,2020,13(1 Pt 1):97-105.

2


3

4

5 **Figure legend:**

6 Figure 1. Study flowchart. CCTA, Coronary computed tomography angiography; FFR,  
7 fractional flow reserve; QFR, Quantitative flow ratio; CT-QFR, CCTA-derived  
8 Quantitative Flow Ratio.

For peer review only




233x239mm (300 x 300 DPI)



Section & Topic	No	Item	Reported on page #
<b>TITLE OR ABSTRACT</b>			
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy: Diagnostic Accuracy of CCTA-derived versus Angiography-derived Quantitative Flow Ratio (CAREER) Study: Rationale and Design	Page 1
<b>ABSTRACT</b>			
	2	Structured summary of study design, methods, results, and conclusions : Background: Coronary computed tomography angiography (CCTA)- derived quantitative flow ratio (CT-QFR) is a novel non-invasive technology to assess the physiological significance of coronary stenoses, which enables fast and onsite computation of fractional flow reserve (FFR) from CCTA images. The objective of this investigator-initiated, prospective, single-center clinical trial is to evaluate the diagnostic performance of CT-QFR with respect to angiography-derived QFR, using FFR as the reference standard. Methods: A total of 216 patients who have at least 1 lesion with a diameter stenosis of 30% to 90% in an artery with $\geq 2.0$ mm reference diameter will be enrolled in the study. FFR will be measured during invasive coronary angiography. CT-QFR, and QFR will be assessed in two independent core laboratories in blinded fashion. The primary endpoint is the diagnostic accuracy of CT-QFR in identifying hemodynamically significant coronary stenosis with FFR as the reference standard. Major secondary endpoint is the non-inferiority of CT-QFR compared with QFR in the patients without extensively calcified lesions. Discussion: This study will be the first study to prospectively validate the diagnostic accuracy of CT-QFR compared with QFR, using FFR as the reference standard.	Page 3
<b>INTRODUCTION</b>			
	3	Scientific and clinical background, including the intended use and clinical role of the index test : Coronary computed tomography angiography (CCTA) is a non-invasive test that enables visualization of coronary anatomy and the characteristics of arterial plaques with high sensitivity and negative predictive value. However, conventional CCTA does not allow for physiological assessment of coronary stenosis. Fractional flow reserve (FFR) is the current gold standard for evaluating the physiological significance of coronary stenosis in the catheterization laboratory. An FFR-guided revascularization strategy was validated with improved clinical outcomes and cost-effectiveness compared to a traditional invasive coronary angiography-guided strategy. The use of FFR is supported by both European guidelines (Class I, Level of Evidence: A) and American guidelines (Class IIa, Level of Evidence: A) in assessing coronary stenosis and to guide revascularization. However, the adoption of FFR was limited due to prolonged procedural time, increased cost, patient discomfort, and operator's confidence in visual assessment from coronary angiograms. Several computational FFR methods were developed to overcome the above limitations. Quantitative flow ratio (QFR), a new method for fast computation of FFR based on invasive coronary angiography (ICA) and empirical fluid dynamic equations was recently developed. The overall diagnostic concordance between QFR and FFR was reported as 87% in a recent meta-analysis of prospective clinical studies. More recently, CCTA-derived QFR, namely CT-QFR, has been developed as a method for fast computation of FFR from CCTA images based on previously validated QFR algorithm. A recent retrospective and observational study demonstrated a good diagnostic concordance of 87%. In addition, its analysis time has been reduced to less than 5 minutes per patient on an off-the-shelf workstation. The diagnostic accuracy of this CT-QFR software version for on-site evaluation of coronary stenosis severity remains unknown. Furthermore, the difference in the diagnostic performance of QFR when applied to non-invasive CCTA images and to ICA has not been studied. We are therefore planning to prospectively validate the diagnostic performance of on-site CT-QFR analysis compared with QFR, using FFR as the reference standard.	Page 4, 5
	4	Study objectives and hypotheses: The primary endpoint of the study is the patient-level diagnostic accuracy of on-site CT-QFR in identifying physiologically significant coronary artery stenosis, using FFR as the reference standard. Major secondary endpoint is the non-inferiority of CT-QFR compared with QFR in the vessels without extensively calcified lesions defined by the combination of a cross-sectional calcium arc $>90^\circ$ and a thickness $>1.5$ mm. Other secondary objectives of the study will include the following. (1) Other common measures of diagnostic performance of CT-QFR, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) at the patient level compared with FFR as the reference standard. (2) Correlation between CT-QFR and FFR. (3) The comparison of the discrimination ability between CT-QFR, CCTA-derived percent	Page 5,6

		diameter stenosis (CTA-DS%), and QCA-derived DS% for identifying physiologically significant stenosis with FFR as the reference standard.	
<b>METHODS</b>			
<i>Study design</i>	<b>5</b>	Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study): This study is an investigator-initiated, prospective, single-center clinical trial to validate the diagnostic performance of on-site CT-QFR using FFR as the reference standard. The study is conducted in accordance with the ethical principles of the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Huadong Hospital Affiliated to Fudan University. Before the study starts, written informed consent form will be obtained from patients willing to participate in the study and approved by the institutional review board/independent ethics committee of Huadong Hospital Affiliated to Fudan University.	Page 5
<i>Participants</i>	<b>6</b>	Eligibility criteria : Inclusion criteria are: (1) at least 1 lesion with DS% between 30% and 90% in a coronary artery with a $\geq 2.0$ mm reference vessel diameter by visual estimation; (2) invasive coronary angiography performed less than 30 days after CCTA; (3) age over 35 years but less than or equal to 85 years. Exclusion criteria are: (1) prior percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) of the interrogated lesion; (2) myocardial bridge involved in the interrogated vessel; (3) presence of collateral flow; (4) severe heart failure (NYHA $\geq$ III); (5) known severe renal failure (eGFR $<$ 30 ml/min/1.73m <sup>2</sup> ); (6) contraindicated to use contrast agents, beta blockers, nitrates or adenosine drugs; (7) Recent prior myocardial infarction within 1 month of CCTA; (8) low image quality CCTA or coronary angiography to be assessed such as motion artifacts, poor filling of contrast agent, etc.; (9) any factors that affect the image quality of CCTA and coronary angiography, such as frequent premature contractions, atrial fibrillation, etc.	Page 5, 6
	<b>7</b>	Potentially eligible participants will be identified on their symptoms and results from previous tests.	Page 5
	<b>8</b>	Where and when potentially eligible participants were identified (setting, location and dates): Recruitment has been ongoing at Huadong Hospital Affiliated to Fudan University, Shanghai, China since December 2020.	Page 5,6
	<b>9</b>	Participants formed a consecutive, convenience series.	Page 5
<i>Test methods</i>	<b>10a</b>	Index test: Coronary computed tomography angiography - derived quantitative flow ratio (CT-QFR); Angiography-derived quantitative flow ratio (QFR)	Page 4, 5
	<b>10b</b>	Reference standard: Fractional flow reserve (FFR).	Page 4, 5
	<b>11</b>	Rationale for choosing the reference standard: Fractional flow reserve (FFR) is the current gold standard for evaluating the physiological significance of coronary stenosis in the catheterization laboratory. An FFR-guided revascularization strategy was validated with improved clinical outcomes and cost-effectiveness compared to a traditional invasive coronary angiography-guided strategy.	Page 4
	<b>12a</b>	Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory : The performances of QFR $\leq$ 0.80 and CT-QFR $\leq$ 0.80 predict hemodynamically significant coronary stenosis.	Page11
	<b>12b</b>	Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory: The performance of FFR $\leq$ 0.80 predicts hemodynamically significant coronary stenosis.	Page11
	<b>13a</b>	Clinical information and reference standard results will not be available to the performers/readers of the index test.	Page 7-10
	<b>13b</b>	Clinical information and index test results will not be available to the assessors of the reference standard.	Page 7-10
<i>Analysis</i>	<b>14</b>	Methods for estimating or comparing measures of diagnostic accuracy : The performance of QFR $\leq$ 0.80 and CT-QFR $\leq$ 0.80 for predicting FFR $\leq$ 0.80 will be assessed by using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (+LR), negative likelihood ratio (-LR), and diagnostic accuracy, together with their 95% confidence intervals (CIs). The ROC curve analysis will be performed to assess area under the curve (AUC) of CT-QFR, QFR, CT-derived %DS and QCA derived %DS for predicting	Page 7-10

1		FFR≤0.80. The ROC curves will be compared by using the DeLong method. A two-side p value <0.05 is considered to indicate statistical significance.	
2			
3	15	How indeterminate index test or reference standard results were handled: When calculating the sample size, the data that could not be completed was included as the dropout rate, which accounted for 15%.	Page 7,8
4			
5			
6	16	How missing data on the index test and reference standard were handled: When calculating the sample size, the data that could not be completed was included as the dropout rate, which accounted for 15%.	Page 7,8
7			
8			
9	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory: Agreements between QFR, CT-QFR, and FFR will be assessed by Bland-Altman plot. The Bland-Altman plot depicts the differences of each pair of measurements versus their mean values with reference lines for the mean difference of all paired measurements. The limits of agreement are defined as mean±1.96 SD of absolute difference	Page 11,12
10			
11			
12			
13			
14			
15			
16	18	Intended sample size and how it was determined: The primary endpoint is the diagnostic accuracy of CT-QFR≤0.8 to identify hemodynamically significant coronary stenosis with FFR≤0.8 as the reference standard. The trial is powered for testing significance of the primary endpoint. The primary null and alternative hypotheses to be tested are H0, diagnostic accuracy of CT-QFR≤0.72, and H1, diagnostic accuracy of CT-QFR > 0.72. Estimates for the sample size calculation are based on the results from the retrospective study of CT-QFR[14], where an accuracy of 87% at patient level was found. In this prospective study, the accuracy is conservatively estimated as 82% for consecutively enrolled patient population, and with a target value set as 72%, which is chosen to be higher than the one in the DeFACTO study[15].The sample size is analysed for paired proportions using the following formula: $N = \frac{[Z_{1-\alpha/2}\sqrt{P_0(1-P_0)} + Z_{1-\beta}\sqrt{P_T(1-P_T)}]^2}{(P_T - P_0)^2}$ With power = 0.90, two-tailed alpha = 0.05, a total of 188 patients with paired CT-QFR and FFR are required to reject the null hypothesis for diagnostic accuracy. To account for incomplete CT-QFR/CT-DS%/FFR/QFR/QCA data of 15% at most, a total of 216 patients need to be enrolled. The major secondary endpoint is to validate the non-inferiority of CT-QFR compared with QFR in the patients without extensively calcified lesions. Analyzed by the enrollment of 216 patients, about 158 patients will be calculated according to the proportion, 26.9%, of extensively calcified lesions from the retrospective study[14]. It will be tested for the capability in achieving the major secondary endpoint. The accuracy of 89.5% for CT-QFR in non-severe calcified lesions[14] and the accuracy of 92.7% for QFR[10] are used to calculate the sample size. We set the non-inferiority threshold as 15%. It will be analyzed by the following formula: $N_T = \frac{(Z_{1-\alpha/2} + Z_{1-\beta})^2 [P_C(1 - P_C) + P_T(1 - P_T)]}{(D - \Delta)^2}$ With power = 0.90, two-tailed alpha = 0.05, a total of 122 patients are required to validate the non-inferiority. To account for incomplete CT-QFR/CTA-DS%/FFR/QFR/QCA data of 15% at most , 141 patients need to be enrolled. Therefore, 158 patients without extensively calcified lesions meet the sample size of the major secondary endpoint. Therefore, the sample size is set as 216 patients to satisfy the requirements for validating both primary and major secondary endpoints.	Page 7,8
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45	<b>RESULTS</b>		
46	<i>Participants</i>	19 Flow of participants, using a diagram:	Page 11
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			



	<b>20</b>	Baseline demographic and clinical characteristics of participants: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	<b>21a</b>	Distribution of severity of disease in those with the target condition: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	<b>21b</b>	Distribution of alternative diagnoses in those without the target condition: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	<b>22</b>	Time interval and any clinical interventions between index test and reference standard: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
<i>Test results</i>	<b>23</b>	Cross tabulation of the index test results (or their distribution) by the results of the reference standard: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	<b>24</b>	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals): This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	<b>25</b>	Any adverse events from performing the index test or the reference standard: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
<b>DISCUSSION</b>	<b>26</b>	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	<b>27</b>	Implications for practice, including the intended use and clinical role of the index test: This study will prospectively validate the diagnostic efficacy of a fast computational approach to derive FFR from coronary CT angiography with can be onsite for the first time. Furthermore, severe calcification will affect the diagnosis of lesions on CT images. It was proved that the presence of extensively calcified lesions influenced the diagnostic accuracy and analysis For peer review only - <a href="http://bmjopen.bmj.com/site/about/guidelines.xhtml">http://bmjopen.bmj.com/site/about/guidelines.xhtml</a>

Page 12-15

BMJ Open: first published as 10.1136/bmjopen-2021-055481 on 23 June 2022. Downloaded from <http://bmjopen.bmj.com/> on August 5, 2024 by guest. Protected by copyright.



variability. Therefore, we intend to avoid the effects of severe calcification so as to define whether CT-QFR is equivalent to QFR. It's also the first time to compare the diagnostic performance of CCTA-derived QFR with angiography-derived QFR.

This study will lay the foundation for future studies to look at the potential value of CT-QFR technology in patients management. If the study achieves the expected objectives, outpatients can receive coronary artery functional evaluation while undergoing CCTA Examination. It can greatly reduce unnecessary invasive coronary angiography and coronary interventions.

#### OTHER INFORMATION

28	Registration number and name of registry: ClinicalTrials.gov Identifier: NCT04665817	Page 5
29	Where the full study protocol can be accessed: This is the protocol manuscript.	
30	Sources of funding and other support; role of funders: CAREER Study is an investigator-initiated clinical trial with external funding from Clinical Research Plan of SHDC (No. SHDC2020CR3024B) issued by Shanghai Hospital Development Center, Research Fund of Huadong Hospital (No. 2019lc015) and a Center of Geratic Coronary Artery Disease.	Page 15



# STARD 2015

---

## AIM

STARD stands for “Standards for Reporting Diagnostic accuracy studies”. This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.

---

## EXPLANATION

A **diagnostic accuracy study** evaluates the ability of one or more medical tests to correctly classify study participants as having **atarget condition**. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.

The test whose accuracy is evaluated is called **index test**. A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the **reference standard**. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.

If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the **sensitivity** of the index test (the proportion of participants *with* the target condition who have a positive index test), and its **specificity** (the proportion *without* the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or “2x2” table), several other accuracy statistics can be estimated, such as the positive and negative **predictive values** of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical **precision** of the measurements.

If the index test results can take more than two values, categorization of test results as positive or negative requires a **test positivity cut-off**. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The **area under the ROC curve** informs in a single numerical value about the overall diagnostic accuracy of the index test.

The **intended use** of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The **clinical role** of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.

Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.

---

## DEVELOPMENT

This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.

More information can be found on <http://www.equator-network.org/reporting-guidelines/stard>.



# BMJ Open

## Diagnostic Accuracy of CCTA-derived versus Angiography-derived Quantitative Flow Ratio (CAREER) Study: A prospective study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-055481.R2
Article Type:	Protocol
Date Submitted by the Author:	28-May-2022
Complete List of Authors:	Weng, Tingwen; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Gan, Qian; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Li, Zehang; Shanghai Jiao Tong University, School of Biomedical Engineering Guan, Shaofeng; Huadong Hospital Affiliated to Fudan University Han, Wenzheng; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Zhai, Xinrong; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Li, Ming; Huadong Hospital Affiliated to Fudan University, Department of Radiology Qi, Lin; Huadong Hospital Affiliated to Fudan University, Department of Radiology Li, Cheng; Huadong Hospital Affiliated to Fudan University, Department of Radiology Chen, Yang; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Zhang, Liang; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Chang, Xifeng; Huadong Hospital Affiliated to Fudan University, Department of Cardiology Tu, Shengxian; Shanghai Jiao Tong University QU, XINKAI; Huadong Hospital Affiliated to Fudan University, Department of Cardiology
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Diagnostics
Keywords:	Adult cardiology < CARDIOLOGY, Coronary heart disease < CARDIOLOGY, Coronary intervention < CARDIOLOGY, Cardiomyopathy < CARDIOLOGY, Ischaemic heart disease < CARDIOLOGY



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

BMJ Open: first published as 10.1136/bmjopen-2021-055481 on 23 June 2022. Downloaded from <http://bmjopen.bmj.com/> on August 5, 2024 by guest. Protected by copyright.



1 **Title: Diagnostic Accuracy of CCTA-derived versus Angiography-derived**  
2 **Quantitative Flow Ratio (CAREER) Study: A prospective study protocol**

3

4

5 Running title: The research protocol of the CAREER study

6

7 Tingwen Weng,<sup>a\*</sup> M.D., Qian Gan,<sup>a\*</sup> M.D. Ph.D., Zehang Li,<sup>b</sup> B.Sc., Shaofeng Guan,<sup>a</sup>  
8 M.D.Ph.D., Wenzheng Han,<sup>a</sup> M.D. Ph.D., Xinrong Zhai,<sup>a</sup> M.D., Ming Li,<sup>c</sup> M.D. Ph.D.,  
9 Lin Qi,<sup>c</sup> M.D., Cheng Li,<sup>c</sup> M.D., Yang Chen,<sup>a</sup> M.D., Liang Zhang,<sup>a</sup> M.D., Xifeng  
10 Chang,<sup>a</sup> M.D., Shengxian Tu,<sup>b</sup> Ph.D., Xinkai Qu,<sup>a</sup> M.D. PhD.

11

12

13 <sup>a</sup> Department of Cardiology, Huadong Hospital Affiliated to Fudan University,  
14 Shanghai, China,

15 <sup>b</sup> Biomedical Instrument Institute, School of Biomedical Engineering, Shanghai Jiao  
16 Tong University, Shanghai, China,

17 <sup>c</sup> Department of Radiology, Huadong Hospital Affiliated to Fudan University, Shanghai,  
18 China.

19

20 \*Equal contributors. Tingwen Weng and Qian Gan contributed equally to this work.

21

22

1  
2  
3  
4 **1 Corresponding author:**  
5

6 2 Xinkai Qu, M.D. Ph.D.  
7

8  
9 3 Huadong Hospital Affiliated to Fudan University  
10

11 4 221 Yan'an W Rd, Jing'an District, Shanghai, China, 200040  
12

13  
14 5 E-mail: [qxkhuadong@sina.com](mailto:qxkhuadong@sina.com) Phone: +86 13916320399  
15

16  
17 6 Shengxian Tu, Ph.D.  
18

19 7 Biomedical Instrument Institute, School of Biomedical Engineering, Shanghai Jiao  
20

21  
22 8 Tong University, Shanghai, China, 200030  
23

24  
25 9 E-mail: [sxtu@sjtu.edu.cn](mailto:sxtu@sjtu.edu.cn) Phone: +86 13681841194  
26

27 10  
28

29  
30 11  
31

32  
33 12  
34

35  
36 13  
37

38  
39 14  
40

41  
42 15  
43

44  
45 16  
46

47  
48 17  
49

50  
51 18  
52

53  
54 19  
55

56  
57 20  
58

59  
60 21  
61

62  
63 22  
64

## 1 **Abstract**

2 **Introduction:** Coronary computed tomography angiography (CCTA)-derived  
3 quantitative flow ratio (CT-QFR) is a novel non-invasive technology to assess the  
4 physiological significance of coronary stenoses, which enables fast and on-site  
5 computation of fractional flow reserve (FFR) from CCTA images. The objective of this  
6 investigator-initiated, prospective, single-center clinical trial is to evaluate the  
7 diagnostic performance of CT-QFR with respect to angiography-derived QFR, using  
8 FFR as the reference standard.

9 **Methods and analysis:** A total of 216 patients who have at least 1 lesion with a  
10 diameter stenosis of 30% to 90% in an artery with  $\geq 2.0$ mm reference diameter will be  
11 enrolled in the study. FFR will be measured during invasive coronary angiography. CT-  
12 QFR and QFR will be assessed in two independent core laboratories in a blinded  
13 fashion. The primary endpoint is the diagnostic accuracy of CT-QFR in identifying  
14 hemodynamically significant coronary stenosis with FFR as the reference standard. The  
15 major secondary endpoint is the non-inferiority of CT-QFR compared with QFR in the  
16 patients without extensively calcified lesions.

17 **Ethics and Dissemination:** The study was approved by the Ethics Committee of  
18 Huadong Hospital Affiliated to Fudan University (2020K192). Outcomes will be  
19 disseminated through publications in peer-reviewed journals and presentations at  
20 scientific conferences.

## 21 **Article summary**

## 22 **Strengths and limitations of this study:**

- 1  
2  
3  
4 1 ➤ The Diagnostic Accuracy of CCTA-derived versus Angiography-derived  
5  
6 2 Quantitative Flow Ratio (CAREER) Study is a prospective and observational  
7  
8  
9 3 study initiated by investigator.  
10  
11 4 ➤ This is a non-inferiority study comparing CT-QFR to QFR.  
12  
13 5 ➤ CT-QFR and QFR will be computed in a blinded fashion and compared with  
14  
15 FFR.  
16  
17 6  
18 7 ➤ Differences in cultural, economic, and social factors that affect patients'  
19  
20 willingness to participate in the study will limit the inclusivity of the population.  
21  
22 8  
23 9 ➤ Due to the tight schedule and insufficient funding, a multi-center study cannot  
24  
25 be conducted at this time.  
26  
27  
28  
29  
30  
31  
32

33 **Keywords:** Coronary computed tomography angiography-derived quantitative flow  
34  
35 ratio ( CT-QFR ) ; Angiography-derived quantitative flow ratio ( QFR ) ; Diagnostic  
36  
37 accuracy; Non-inferiority  
38  
39

40 **Trial registration:** ClinicalTrials.gov Identifier: NCT04665817  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 1 Introduction

2 Coronary computed tomography angiography (CCTA) is a noninvasive test that  
3 enables visualization of coronary anatomy and the characteristics of arterial plaques  
4 with high sensitivity and negative predictive value<sup>[1]</sup>. However, conventional CCTA  
5 does not allow for physiological assessment of coronary stenosis<sup>[2]</sup>. Fractional flow  
6 reserve (FFR) is the current gold standard for evaluating the physiological significance  
7 of coronary stenosis in the catheterization laboratory<sup>[3]</sup>. An FFR-guided  
8 revascularization strategy was validated with improved clinical outcomes and cost-  
9 effectiveness compared to a traditional invasive coronary angiography-guided strategy  
10<sup>[4-7]</sup>. The use of FFR is supported by both European guidelines (Class I, Level of  
11 Evidence: A) and American guidelines (Class IIa, Level of Evidence: A) in assessing  
12 coronary stenosis and guiding revascularization<sup>[8]</sup>. However, the adoption of FFR was  
13 limited due to prolonged procedural time, increased cost, patient discomfort, and  
14 operator's confidence in visual assessment from coronary angiograms.

15 Several computational FFR methods were developed to overcome the above  
16 limitations. Quantitative flow ratio (QFR), a new method for fast computation of FFR  
17 based on invasive coronary angiography (ICA) and empirical fluid dynamic equations  
18 was recently developed<sup>[9]</sup>. The overall diagnostic concordance between QFR and FFR  
19 was reported as 87% in a recent meta-analysis of prospective clinical studies<sup>[10]</sup>.

20 More recently, CCTA-derived QFR, namely CT-QFR, has been developed as a  
21 method for fast computation of FFR from CCTA images based on a previously  
22 validated QFR algorithm. A recent retrospective and observational study demonstrated

1 a good diagnostic concordance of 87% [11]. In addition, its analysis time has been  
2 reduced to less than 5 minutes per patient on an off-the-shelf workstation. The  
3 diagnostic accuracy of this CT-QFR software version for on-site evaluation of coronary  
4 stenosis severity remains unknown. Furthermore, the differences in the diagnostic  
5 performance of QFR when applied to noninvasive CCTA images and ICA have not  
6 been studied. We are therefore planning to prospectively validate the diagnostic  
7 performance of on-site CT-QFR analysis compared with QFR, using FFR as the  
8 reference standard.

## 10 **Methods and analysis**

### 11 **Study design**

12 This study is an investigator-initiated, prospective, single-center clinical trial to  
13 validate the diagnostic performance of on-site CT-QFR using FFR as the reference  
14 standard. The study is conducted in accordance with the ethical principles of the  
15 Declaration of Helsinki. The study protocol was approved by the Ethics Committee of  
16 Huadong Hospital Affiliated to Fudan University. Before the study starts, a written  
17 informed consent form will be obtained from patients willing to participate in the study  
18 and approved by the institutional review board/independent ethics committee of  
19 Huadong Hospital Affiliated to Fudan University (2020K192). The protocol of the trial  
20 has been registered at <http://clinicaltrials.gov> (NCT04665817).

### 22 **Study objectives**

1 The primary endpoint of the study is the patient-level diagnostic accuracy of on-  
2 site CT-QFR in identifying physiologically significant coronary artery stenosis, using  
3 FFR as the reference standard. The major secondary endpoint is the non-inferiority of  
4 CT-QFR compared with QFR in the vessels without extensively calcified lesions  
5 defined by the combination of a cross-sectional calcium arc  $> 90^\circ$  and a thickness  $> 1.5$   
6 mm. Other secondary objectives of the study will include the following: (1) Other  
7 common measures of diagnostic performance of CT-QFR, including sensitivity,  
8 specificity, positive predictive value (PPV), and negative predictive value (NPV) at the  
9 patient level compared with FFR as the reference standard. (2) Correlation between CT-  
10 QFR and FFR. (3) The comparison of the discrimination ability between CT-QFR,  
11 CCTA-derived percent diameter stenosis (CTA-DS%), and QCA-derived DS% for  
12 identifying physiologically significant stenosis with FFR as the reference standard.

### 14 **Patient population**

15 Patients with stable or unstable angina pectoris or non-acute phase of myocardial  
16 infarction who are undergoing CCTA examination and scheduled for coronary  
17 angiography within 30 days will be screened. We require the interval between ICA and  
18 CCTA to be less than 30 days which was in line with previous studies on CCTA-based  
19 FFR<sup>[12, 13]</sup> to avoid a mismatch between CCTA images and invasive coronary  
20 angiography images due to the progression of the patient's coronary artery stenosis.  
21 Inclusion criteria are: (1) at least 1 lesion with DS% between 30% and 90% in a  
22 coronary artery with a  $\geq 2.0$ mm reference vessel diameter by visual estimation; (2)

1  
2  
3  
4 1 invasive coronary angiography performed less than 30 days after CCTA; (3) age over  
5  
6 2 35 years but less than or equal to 85 years. Exclusion criteria are: (1) prior percutaneous  
7  
8  
9 3 coronary intervention (PCI) or coronary artery bypass graft (CABG) of the interrogated  
10  
11 4 lesion; (2) myocardial bridge involved in the interrogated vessel; (3) presence of  
12  
13 5 collateral flow; (4) severe heart failure (NYHA  $\geq$ III); (5) known severe renal failure  
14  
15 6 (eGFR  $<$  30 ml/min/1.73m<sup>2</sup>); (6) contraindicated to use contrast agents, beta-blockers,  
16  
17 7 nitrates, or adenosine drugs; (7) recent prior myocardial infarction within 1 month of  
18  
19 8 CCTA; (8) low image quality CCTA or coronary angiography to be assessed such as  
20  
21 9 motion artifacts, poor filling of contrast agent, etc.; (9) any factors that affect the image  
22  
23 10 quality of CCTA and coronary angiography, such as frequent premature contractions,  
24  
25 11 atrial fibrillation, etc. Patients with comorbidities such as diabetes mellitus,  
26  
27 12 hypertension or other chronic diseases, in particular, will not be excluded in this study  
28  
29 13 because the coronary hemodynamics and image quality of CCTA and ICA will not be  
30  
31 14 significantly influenced by these comorbidities.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 16 **Statistical hypotheses and Sample Size Calculation**

17 The primary endpoint is the diagnostic accuracy of CT-QFR  $\leq$  0.8 to identify  
18 hemodynamically significant coronary stenosis with FFR  $\leq$  0.8 as the reference  
19 standard. The trial is powered for testing the significance of the primary endpoint. The  
20 primary null and alternative hypotheses to be tested are H<sub>0</sub>, diagnostic accuracy of CT-  
21 QFR  $\leq$  0.72, and H<sub>1</sub>, diagnostic accuracy of CT-QFR  $>$  0.72. Estimates for the sample  
22 size calculation are based on the results from the retrospective study of CT-QFR<sup>[11]</sup>,



1 where an accuracy of 87% at the patient level was found. In this prospective study, the  
 2 accuracy is conservatively estimated as 82% for the consecutively enrolled patient  
 3 population, and with a target value set as 72%, which is chosen to be higher than the  
 4 one in the DeFACTO study<sup>[14]</sup>. The sample size is analyzed for paired proportions using  
 5 the following formula:

$$N = \frac{[Z_{1-\alpha/2}\sqrt{P_0(1-P_0)} + Z_{1-\beta}\sqrt{P_T(1-P_T)}]^2}{(P_T - P_0)^2}$$

7 With power = 0.90, two-tailed alpha = 0.05, a total of 188 patients with paired CT-QFR  
 8 and FFR are required to reject the null hypothesis for diagnostic accuracy. To account  
 9 for incomplete CT-QFR/CT-DS%/FFR/QFR/QCA data of 15% at most, a total of 216  
 10 patients needs to be enrolled.

11 The major secondary endpoint is to validate the non-inferiority of CT-QFR compared  
 12 with QFR in the patients without extensively calcified lesions. Analyzed by the  
 13 enrollment of 216 patients, about 158 patients will be calculated according to the  
 14 proportion, 26.9%, of extensively calcified lesions from the retrospective study<sup>[11]</sup>. It  
 15 will be tested for the capability of achieving the major secondary endpoint. The  
 16 accuracy of 89.5% for CT-QFR in non-severe calcified lesions<sup>[11]</sup> and the accuracy of  
 17 92.7% for QFR<sup>[15]</sup> are used to calculate the sample size. We set the non-inferiority  
 18 threshold as 15%. It will be analyzed by the following formula:

$$N_T = \frac{(Z_{1-\alpha/2} + Z_{1-\beta})^2 [P_C(1 - P_C) + P_T(1 - P_T)]}{(D - \Delta)^2}$$

20 With power = 0.90, two-tailed alpha = 0.05, a total of 122 patients are required to  
 21 validate the non-inferiority. To account for incomplete CT-QFR/CTA-

1 DS%/FFR/QFR/QCA data of 15% at most , 141 patients need to be enrolled. Therefore,  
2 158 patients without extensively calcified lesions meet the sample size of the major  
3 secondary endpoint. Thus, the sample size is set as 216 patients to satisfy the  
4 requirements for validating both primary and major secondary endpoints.

### 6 **CCTA and CTA-DS% Analysis**

7 Coronary computed tomography angiography will be performed on a dual-source  
8 CT system (SOMATOM Drive; Siemens Healthineers, Erlangen, Germany) or a 256  
9 detector row scanners CT system (Revolution CT; GE Healthcare) with prospective or  
10 retrospective electrocardiographic gating in accordance with Society of Cardiovascular  
11 Computed Tomography guidelines<sup>[16]</sup>. Image interpretation of CCTA will be conducted  
12 in a blinded fashion by an experienced investigator. Images with coronary artery  
13 stenosis detected visually will be further analyzed (CtaPlus; version 1.0, Pulse Medical  
14 Imaging Technology, Shanghai, China). Coronary stenosis will be quantified by using  
15 the following parameters: (i) the minimal lumen area (MLA) and the minimal lumen  
16 diameter (MLD), and (ii) the percentage diameter stenosis (DS%) and the percentage  
17 area stenosis (AS%).

### 19 **CT- QFR Computation**

20 CT-QFR computation will be performed by experienced analysts using a recently  
21 developed software package (CtaPlus, version 1.0; Pulse Medical Imaging Technology,  
22 Shanghai, China), blinded to both QFR and FFR data. Detailed methodologies for CT-

1 QFR computation have been published previously<sup>[11]</sup>. A recent upgrade in the CT-QFR  
2 algorithm integrated deep learning technique into the coronary segmentation method to  
3 improve the computation efficiency. Manual corrections are allowed if the automated  
4 delineation lumen contour is sub-optimal, particularly at the segment with calcified  
5 plaques. All coronary artery segments with reference lumen diameter  $\geq 1.5$  mm are  
6 analyzed. Subsequently, all the delineated coronary branches are automatically merged  
7 for the reconstruction of the entire coronary tree, based on which the healthy reference  
8 lumen is also reconstructed. Finally, the CT-QFR value at each position of the coronary  
9 tree is computed using the previously validated QFR algorithm<sup>[9, 17]</sup>.

### 11 **Coronary Angiography**

12 Coronary angiography will be performed by using a 5- or 6-F catheter with a  
13 transfemoral or transradial approach. All patients will receive an intravenous injection  
14 of heparin 100 IU/kg before angiography. Contrast media (Omnipaque 350 injection,  
15 GE Healthcare, Shanghai, China) will be injected manually with a forceful and stable  
16 injection. Coronary angiograms will be obtained from standard series of 6 to 8  
17 projections for the left coronary artery and 2 or 3 projections for the right coronary  
18 artery by using a monoplane or biplane radiographic system (AXIOM Artis FC and  
19 Artis zee Biplane MN, Siemens) at 15 frames/s. All images will be digitally stored for  
20 analysis.

### 22 **FFR Measurement**

1  
2  
3  
4 1 Intracoronary pressure will be measured by using a RadiAnalyzer Xpress  
5  
6 2 instrument and Certus pressure wire (St. Jude Medical, Plymouth, Minnesota). The  
7  
8  
9 3 pressure guidewire will be introduced into the coronary artery and positioned distal to  
10  
11 4 the coronary stenosis. The position of the sensor of the pressure guidewire will be  
12  
13  
14 5 recorded on cine fluorography. Hyperemia will be induced by adenosine-5'-  
15  
16 6 triphosphate (ATP) infusion (160 µg/kg/minute) through an antecubital vein over a  
17  
18  
19 7 minimum of 2 minutes. During steady-state hyperemia, mean proximal aortic pressure,  
20  
21  
22 8 and mean intracoronary pressure distal to the target stenosis will be measured.  
23  
24  
25 9 Subsequently, the pressure guidewire will be slowly pulled back from the most distal  
26  
27  
28 10 to the proximal part of the artery by manual procedure during steady-state maximal  
29  
30  
31 11 hyperemia. If the pressures are not equalized at the end of the pullback (i.e., the pressure  
32  
33 12 drift  $|Pa-Pd| > 3$  mmHg), the whole FFR measurements should be repeated from the  
34  
35 13 beginning.  
36  
37  
38 14

### 15 **QCA Analysis and QFR Computation**

16 Quantitative coronary angiographic (QCA) analysis and QFR computation will be  
17 performed in a blinded fashion by using the recently developed QFR analysis system  
18 (AngioPlus Core; Pulse Medical Imaging Technology, Shanghai, China). The  
19 computational methods were previously described<sup>[9, 15]</sup>. Same as CT-DS% analysis,  
20 QCA analysis includes the following parameters: (i) MLA and MLD, and (ii) DS% and  
21 AS%. It will be analyzed by well-trained technicians who have successfully completed  
22 QFR training. Before QFR analysis, the technicians will be informed about the location

1 where the operators measured FFR so that QFR could be measured at the same vessel  
2 site. The QFR measure will be performed on the system placed in the control room.  
3 The investigators will be blinded to the FFR results.

#### 4 **Study flowchart**

5 A study flowchart is shown in Figure 1.

#### 6 **Statistical Analysis**

7 Continuous variables are presented as mean  $\pm$  SD, and categorical variables will  
8 be presented as counts and percentages. Sensitivity and specificity to predict  
9 functionally significant stenosis ( $\text{FFR} \leq 0.80$ ). The performance of  $\text{QFR} \leq 0.80$  and CT-  
10  $\text{QFR} \leq 0.80$  for predicting  $\text{FFR} \leq 0.80$  will be assessed by using sensitivity, specificity,  
11 positive predictive value (PPV), negative predictive value (NPV), positive likelihood  
12 ratio (+LR), negative likelihood ratio (-LR), and diagnostic accuracy, together with  
13 their 95% confidence intervals (CIs). Pearson correlation or spearman's correlation will  
14 be used to quantify the correlations between QFR, CT-QFR, and FFR. Agreements  
15 between QFR, CT-QFR, and FFR will be assessed by the Bland-Altman plot. The  
16 Bland-Altman plot depicts the differences of each pair of measurements versus their  
17 mean values with reference lines for the mean difference of all paired measurements.  
18 The limits of the agreement will be defined as mean  $\pm$  1.96 SD of absolute difference.  
19 The ROC curve analysis will be performed to assess the area under the curve (AUC) of  
20 CT-QFR, QFR, CT-derived %DS, and QCA-derived %DS for predicting  $\text{FFR} \leq 0.80$ .  
21 The ROC curves will be compared by using the DeLong method. A two-sided p-value  
22  $< 0.05$  will be considered to indicate statistical significance.

## 1 **Current status**

2 The study has been approved by the Ethics Committee of Huadong Hospital  
3 Affiliated to Fudan University. Five analysts have successfully completed the  
4 International Course on Coronary Image Analysis and Computational Physiology  
5 which covers FFR, QFR, and CT-QFR. All of them have passed the final exams (with  
6 the diagnostic accuracy higher than 85% and the standard deviation of mean difference  
7 less than 0.05 between image-based FFR and invasive FFR) and obtained qualification  
8 certificates for relevant analysis. Recruitment is ongoing at Huadong Hospital  
9 Affiliated to Fudan University, Shanghai, China. At the time of submission of this  
10 manuscript, 35 participants have been recruited for the study.

## 11 **Discussion**

12 The CAREER study will for the first time prospectively evaluate the diagnostic  
13 accuracy of on-site CT-QFR analysis in identifying patients with physiologically  
14 significant coronary stenosis. In addition, the diagnostic performance of CCTA-based  
15 versus angiography-based QFR in vessels without significantly calcified lesions will be  
16 compared. The study findings will provide pivotal data to support the clinical  
17 applications of CT-QFR in the management of CAD patients.

18 The previously presented FFR computation method derived from computed  
19 tomography (FFR<sub>CT</sub>), a non-invasive technology, is a computational fluid dynamic  
20 modeling technique that enables the calculation of FFR from a coronary computed  
21 tomographic angiographic dataset<sup>[18]</sup>. The diagnostic performance of FFR<sub>CT</sub> has been  
22

1 validated in several multi-center prospective clinical trials<sup>[12, 19, 20]</sup>. The application of  
2 FFR<sub>CT</sub> can reduce unnecessary invasive coronary angiography<sup>[21, 22]</sup>. However, it  
3 heavily relies on the quality of the underlying computational models and sophisticated  
4 boundary conditions and required a few hours for computation<sup>[20]</sup>. Moreover, severely  
5 calcified lesions might affect the calculation results of FFR<sub>CT</sub><sup>[23]</sup>.

6 Recently, a novel technique for the rapid computation of FFR from radiographic  
7 coronary angiography, named QFR, was accomplished by estimating the pressure drop  
8 due to coronary stenosis according to coronary lumen morphology and virtual  
9 hyperemic flow derived from contrast frame count without the use of pressure wire and  
10 drug-induced hyperemia<sup>[9]</sup>. The diagnostic performance of this minimally invasive  
11 technique has been validated by several studies<sup>[9, 15, 24, 25]</sup>. More recently, the novel QFR  
12 algorithm has been applied to CCTA-images, and CCTA-derived QFR (namely CT-  
13 QFR), has been derived as a non-invasive technology to assess the physiological  
14 significance of coronary stenoses<sup>[10]</sup>. The patient-specific virtual hyperemic flow was  
15 used to compute the CT-QFR value at every position of the reconstructed coronary tree.  
16 A recent retrospective and observational study with 156 vessels from 134 patients  
17 demonstrated good correlation ( $r = 0.79$ ;  $p < 0.001$ ) and agreement ( $0.00 \pm 0.06$ ;  $p =$   
18  $0.823$ ) between CT-QFR and wire-based FFR, with a vessel-level diagnostic  
19 concordance of 87%<sup>[11]</sup>. The average analysis time for CT-QFR was reported as less  
20 than 20 minutes, with the CT-QFR pullback curve computed in less than 20 seconds  
21 <sup>[11]</sup>.

22 A recent upgrade in the CT-QFR algorithm integrated deep learning technique into

1  
2  
3  
4 1 the coronary segmentation method thus improving the accuracy of automatic lumen  
5  
6 2 delineation and reducing the analysis time to less than 5 minutes per patient on an off-  
7  
8  
9 3 the-shelf workstation. The incorporation of the deep learning techniques in the CT-QFR  
10  
11 4 algorithm had the potential to improve the calculation efficiency significantly. Large-  
12  
13  
14 5 scale studies have shown that the application of CT-FFR can reduce unnecessary  
15  
16  
17 6 invasive coronary angiography. At the same time, it brings higher health and economic  
18  
19 7 benefits<sup>[21, 26]</sup>. The one-year follow-up of the ADVANCE study showed that the MACE  
20  
21 8 of patients with a CT-FFR value  $\leq 0.8$  was significantly higher than that of patients  
22  
23 9 with a CT-FFR value  $> 0.8$ <sup>[27]</sup>. Therefore, a kind of strategy pertaining more to a rapid  
24  
25  
26  
27 10 diagnosis, reduced invasive strategy, and lower costs is particularly important. This  
28  
29  
30 11 study will prospectively validate the diagnostic efficacy of such a faster computational  
31  
32 12 approach to derive FFR from coronary CT angiography with can be onsite for the first  
33  
34  
35 13 time.

36  
37  
38 14 Furthermore, severe calcification will affect the diagnosis of lesions on CT images.  
39  
40 15 It was proved that the presence of extensively calcified lesions influenced the diagnostic  
41  
42 16 accuracy and analysis variability<sup>[11]</sup>. Therefore, we intend to avoid the effects of severe  
43  
44 17 calcification so as to define whether CT-QFR is equivalent to QFR. It's also the first  
45  
46 18 time to compare the diagnostic performance of CCTA-derived QFR with angiography-  
47  
48 19 derived QFR. Therefore, the major secondary endpoint was intended to investigate the  
49  
50 20 non-inferiority of CT-QFR compared with QFR in the patients without extensively  
51  
52 21 calcified lesions.

53  
54  
55  
56  
57  
58 22 This study will lay the foundation for future studies to look at the potential value  
59  
60



1 of CT-QFR technology in patient management. If the study achieves the expected  
2 objectives, outpatients can receive coronary artery functional evaluation while  
3 undergoing CCTA Examination. It can greatly reduce unnecessary invasive coronary  
4 angiography and coronary interventions.

#### 5 **Ethics and dissemination**

6 This research will not increase the risk and economic burden on patients and the  
7 patients' rights will be fully protected. The study is conducted in accordance with the  
8 ethical principles of the Declaration of Helsinki. The study protocol was approved by  
9 the Ethics Committee of Huadong Hospital Affiliated to Fudan University (ref. number  
10 2020K192). All patients will provide written informed consent. The results of this study  
11 are to be published in respected, peer-reviewed journals, and the findings presented at  
12 scientific conferences in the field of Cardiology.

#### 14 **Acknowledgments**

15 We thank the colleagues in the departments participating in this study.

#### 16 **Funding resources:**

17 Funding: CAREER Study is an investigator-initiated clinical trial with external funding  
18 from the Clinical Research Plan of SHDC ( No. SHDC2020CR3024B ) issued by  
19 Shanghai Hospital Development Center, Research Fund of Huadong Hospital (No.  
20 2019lc015), and a Center of Geriatric Coronary Artery Disease.

#### 21 **Author Contributions**

22 Xinkai Qu and Shenxian Tu participated in the study design, statistical hypotheses, and

1  
2  
3  
4 1 sample size calculation. Tingwen Weng and Qian Gan participated in manuscript  
5  
6 2 preparation, sample size calculation, and writing the protocol of FFR measurement.  
7  
8  
9 3 Zehang Li was involved in manuscript preparation, writing the protocol of QFR  
10  
11 4 computation, and CT-QFR computation. XinrongZhai was involved in writing the  
12  
13 5 protocol of FFR measurement. Ming Li, Lin Qi, and Cheng Li participated in writing  
14  
15 6 the protocol of CCTA Analysis. Shaofeng Guan, Wenzheng Han, Yang Chen, Liang  
16  
17 7 Zhang, and Xifeng Chang were involved in writing the protocol of coronary  
18  
19 8 angiography.  
20  
21  
22  
23  
24

### 25 **Conflict of interest**

26  
27 10 The authors declare that they have no conflict of interest.  
28  
29

### 30 **Data Availability Statement**

31  
32 12 The data will be available from the corresponding author upon a reasonable request.  
33  
34

### 35 **Patient and Public Involvement**

36  
37 14 Patients or the public will be involved in the design, conduct, reporting, or  
38  
39 15 dissemination plans of our research.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

### 50 **References**

51  
52 20 [1] Miller J M, Rochitte C E, Dewey M, et al. Diagnostic performance of coronary  
53  
54 21 angiography by 64-row CT[J]. N Engl J Med,2008,359(22):2324-2336.  
55  
56

57 22 [2] Shaw L J, Berman D S, Maron D J, et al. Optimal medical therapy with or without  
58  
59  
60

1 percutaneous coronary intervention to reduce ischemic burden: results from the  
2 Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation  
3 (COURAGE) trial nuclear substudy[J]. *Circulation*,2008,117(10):1283-1291.

4 [3] Kern M J, Samady H. Current concepts of integrated coronary physiology in the  
5 catheterization laboratory[J]. *J Am Coll Cardiol*,2010,55(3):173-185.

6 [4] Tonino P A, Fearon W F, De Bruyne B, et al. Angiographic versus functional  
7 severity of coronary artery stenoses in the FAME study fractional flow reserve versus  
8 angiography in multivessel evaluation[J]. *J Am Coll Cardiol*,2010,55(25):2816-2821.

9 [5] Tonino P A, De Bruyne B, Pijls N H, et al. Fractional flow reserve versus  
10 angiography for guiding percutaneous coronary intervention[J]. *N Engl J*  
11 *Med*,2009,360(3):213-224.

12 [6] De Bruyne B, Pijls N H, Bartunek J, et al. Fractional flow reserve in patients with  
13 prior myocardial infarction[J]. *Circulation*,2001,104(2):157-162.

14 [7] Xaplanteris P, Fournier S, Pijls N, et al. Five-Year Outcomes with PCI Guided by  
15 Fractional Flow Reserve[J]. *N Engl J Med*,2018,379(3):250-259.

16 [8] Neumann F J, Sousa-Uva M, Ahlsson A, et al. [2018 ESC/EACTS Guidelines on  
17 myocardial revascularization. The Task Force on myocardial revascularization of the  
18 European Society of Cardiology (ESC) and European Association for Cardio-  
19 Thoracic Surgery (EACTS)][J]. *G Ital Cardiol (Rome)*,2019,20(7-8 Suppl 1):1S-61S.

20 [9] Tu S, Westra J, Yang J, et al. Diagnostic Accuracy of Fast Computational  
21 Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary  
22 Angiography: The International Multicenter FAVOR Pilot Study[J]. *JACC*

- 1  
2  
3  
4 1 Cardiovasc Interv,2016,9(19):2024-2035.
- 5  
6 [10] Westra J, Tu S, Campo G, et al. Diagnostic performance of quantitative flow ratio  
7  
8  
9 3 in prospectively enrolled patients: An individual patient-data meta-analysis[J].  
10  
11  
12 4 Catheter Cardiovasc Interv,2019,94(5):693-701.
- 13  
14 [11] Li Z, Zhang J, Xu L, et al. Diagnostic Accuracy of a Fast Computational Approach  
15  
16  
17 6 to Derive Fractional Flow Reserve From Coronary CT Angiography[J]. JACC  
18  
19  
20 7 Cardiovasc Imaging,2020,13(1 Pt 1):172-175.
- 21  
22 [12] Koo B K, Erglis A, Doh J H, et al. Diagnosis of ischemia-causing coronary  
23  
24  
25 9 stenoses by noninvasive fractional flow reserve computed from coronary computed  
26  
27  
28 10 tomographic angiograms. Results from the prospective multicenter DISCOVER-  
29  
30  
31 11 FLOW (Diagnosis of Ischemia-Causing Stenoses Obtained Via Noninvasive  
32  
33  
34 12 Fractional Flow Reserve) study[J]. J Am Coll Cardiol,2011,58(19):1989-1997.
- 35  
36 [13] Wang Z Q, Zhou Y J, Zhao Y X, et al. Diagnostic accuracy of a deep learning  
37  
38  
39 14 approach to calculate FFR from coronary CT angiography[J]. J Geriatr  
40  
41  
42 15 Cardiol,2019,16(1):42-48.
- 43  
44 [14] Min J K, Berman D S, Budoff M J, et al. Rationale and design of the DeFACTO  
45  
46  
47 17 (Determination of Fractional Flow Reserve by Anatomic Computed Tomographic  
48  
49  
50 18 Angiography) study[J]. J Cardiovasc Comput Tomogr,2011,5(5):301-309.
- 51  
52 [15] Xu B, Tu S, Qiao S, et al. Diagnostic Accuracy of Angiography-Based Quantitative  
53  
54  
55 20 Flow Ratio Measurements for Online Assessment of Coronary Stenosis[J]. J Am Coll  
56  
57  
58 21 Cardiol,2017,70(25):3077-3087.
- 59  
60 [16] Leipsic J, Abbara S, Achenbach S, et al. SCCT guidelines for the interpretation

- 1 and reporting of coronary CT angiography: a report of the Society of Cardiovascular  
2 Computed Tomography Guidelines Committee[J]. J Cardiovasc Comput  
3 Tomogr,2014,8(5):342-358.
- 4 [17] Tu S, Ding D, Chang Y, et al. Diagnostic accuracy of quantitative flow ratio for  
5 assessment of coronary stenosis significance from a single angiographic view: A  
6 novel method based on bifurcation fractal law[J]. Catheter Cardiovasc Interv,2021.
- 7 [18] Taylor C A, Fonte T A, Min J K. Computational fluid dynamics applied to cardiac  
8 computed tomography for noninvasive quantification of fractional flow reserve:  
9 scientific basis[J]. J Am Coll Cardiol,2013,61(22):2233-2241.
- 10 [19] Nakazato R, Park H B, Berman D S, et al. Noninvasive fractional flow reserve  
11 derived from computed tomography angiography for coronary lesions of intermediate  
12 stenosis severity: results from the DeFACTO study[J]. Circ Cardiovasc  
13 Imaging,2013,6(6):881-889.
- 14 [20] Nørgaard B L, Leipsic J, Gaur S, et al. Diagnostic performance of noninvasive  
15 fractional flow reserve derived from coronary computed tomography angiography in  
16 suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow  
17 Using CT Angiography: Next Steps)[J]. J Am Coll Cardiol,2014,63(12):1145-1155.
- 18 [21] Douglas P S, Pontone G, Hlatky M A, et al. Clinical outcomes of fractional flow  
19 reserve by computed tomographic angiography-guided diagnostic strategies vs. usual  
20 care in patients with suspected coronary artery disease: the prospective longitudinal  
21 trial of FFR(CT): outcome and resource impacts study[J]. Eur Heart  
22 J,2015,36(47):3359-3367.

- 1  
2  
3  
4 [22] Lu M T, Ferencik M, Roberts R S, et al. Noninvasive FFR Derived From  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 1 [22] Lu M T, Ferencik M, Roberts R S, et al. Noninvasive FFR Derived From  
2 Coronary CT Angiography: Management and Outcomes in the PROMISE Trial[J].  
3 JACC Cardiovasc Imaging,2017,10(11):1350-1358.
- 4 [23] Nørgaard B L, Leipsic J, Koo B K, et al. Coronary Computed Tomography  
5 Angiography Derived Fractional Flow Reserve and Plaque Stress[J]. Curr Cardiovasc  
6 Imaging Rep,2016,9:2.
- 7 [24] Westra J, Andersen B K, Campo G, et al. Diagnostic Performance of In-Procedure  
8 Angiography-Derived Quantitative Flow Reserve Compared to Pressure-Derived  
9 Fractional Flow Reserve: The FAVOR II Europe-Japan Study[J]. J Am Heart  
10 Assoc,2018,7(14).
- 11 [25] Westra J, Tu S, Winther S, et al. Evaluation of Coronary Artery Stenosis by  
12 Quantitative Flow Ratio During Invasive Coronary Angiography: The WIFI II Study  
13 (Wire-Free Functional Imaging II)[J]. Circ Cardiovasc Imaging,2018,11(3):e7107.
- 14 [26] Hlatky M A, De Bruyne B, Pontone G, et al. Quality-of-Life and Economic  
15 Outcomes of Assessing Fractional Flow Reserve With Computed Tomography  
16 Angiography: PLATFORM[J]. J Am Coll Cardiol,2015,66(21):2315-2323.
- 17 [27] Patel M R, Nørgaard B L, Fairbairn T A, et al. 1-Year Impact on Medical Practice  
18 and Clinical Outcomes of FFR(CT): The ADVANCE Registry[J]. JACC Cardiovasc  
19 Imaging,2020,13(1 Pt 1):97-105.

1  
2  
3  
4 1 Figure legend:  
5


6 2 Figure 1. Study flowchart. CCTA, Coronary computed tomography angiography;  
7

8  
9 3 FFR, fractional flow reserve; QFR, Quantitative flow ratio; CT-QFR, CCTA-derived  
10

11 4 Quantitative Flow Ratio.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



233x239mm (300 x 300 DPI)

BMJ Open: first published as 10.1136/bmjopen-2021-055481 on 23 June 2022. Downloaded from <http://bmjopen.bmj.com/> on August 5, 2024 by guest. Protected by copyright.




Section & Topic	No	Item	Reported on page #
<b>TITLE OR ABSTRACT</b>			
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy: Diagnostic Accuracy of CCTA-derived versus Angiography-derived Quantitative Flow Ratio (CAREER) Study: Rationale and Design	Page 1
<b>ABSTRACT</b>			
	2	Structured summary of study design, methods, results, and conclusions : Background: Coronary computed tomography angiography (CCTA)- derived quantitative flow ratio (CT-QFR) is a novel non-invasive technology to assess the physiological significance of coronary stenoses, which enables fast and onsite computation of fractional flow reserve (FFR) from CCTA images. The objective of this investigator-initiated, prospective, single-center clinical trial is to evaluate the diagnostic performance of CT-QFR with respect to angiography-derived QFR, using FFR as the reference standard. Methods: A total of 216 patients who have at least 1 lesion with a diameter stenosis of 30% to 90% in an artery with $\geq 2.0$ mm reference diameter will be enrolled in the study. FFR will be measured during invasive coronary angiography. CT-QFR, and QFR will be assessed in two independent core laboratories in blinded fashion. The primary endpoint is the diagnostic accuracy of CT-QFR in identifying hemodynamically significant coronary stenosis with FFR as the reference standard. Major secondary endpoint is the non-inferiority of CT-QFR compared with QFR in the patients without extensively calcified lesions. Discussion: This study will be the first study to prospectively validate the diagnostic accuracy of CT-QFR compared with QFR, using FFR as the reference standard.	Page 3
<b>INTRODUCTION</b>			
	3	Scientific and clinical background, including the intended use and clinical role of the index test : Coronary computed tomography angiography (CCTA) is a non-invasive test that enables visualization of coronary anatomy and the characteristics of arterial plaques with high sensitivity and negative predictive value. However, conventional CCTA does not allow for physiological assessment of coronary stenosis. Fractional flow reserve (FFR) is the current gold standard for evaluating the physiological significance of coronary stenosis in the catheterization laboratory. An FFR-guided revascularization strategy was validated with improved clinical outcomes and cost-effectiveness compared to a traditional invasive coronary angiography-guided strategy. The use of FFR is supported by both European guidelines (Class I, Level of Evidence: A) and American guidelines (Class IIa, Level of Evidence: A) in assessing coronary stenosis and to guide revascularization. However, the adoption of FFR was limited due to prolonged procedural time, increased cost, patient discomfort, and operator's confidence in visual assessment from coronary angiograms. Several computational FFR methods were developed to overcome the above limitations. Quantitative flow ratio (QFR), a new method for fast computation of FFR based on invasive coronary angiography (ICA) and empirical fluid dynamic equations was recently developed. The overall diagnostic concordance between QFR and FFR was reported as 87% in a recent meta-analysis of prospective clinical studies. More recently, CCTA-derived QFR, namely CT-QFR, has been developed as a method for fast computation of FFR from CCTA images based on previously validated QFR algorithm. A recent retrospective and observational study demonstrated a good diagnostic concordance of 87%. In addition, its analysis time has been reduced to less than 5 minutes per patient on an off-the-shelf workstation. The diagnostic accuracy of this CT-QFR software version for on-site evaluation of coronary stenosis severity remains unknown. Furthermore, the difference in the diagnostic performance of QFR when applied to non-invasive CCTA images and to ICA has not been studied. We are therefore planning to prospectively validate the diagnostic performance of on-site CT-QFR analysis compared with QFR, using FFR as the reference standard.	Page 4, 5
	4	Study objectives and hypotheses: The primary endpoint of the study is the patient-level diagnostic accuracy of on-site CT-QFR in identifying physiologically significant coronary artery stenosis, using FFR as the reference standard. Major secondary endpoint is the non-inferiority of CT-QFR compared with QFR in the vessels without extensively calcified lesions defined by the combination of a cross-sectional calcium arc $>90^\circ$ and a thickness $>1.5$ mm. Other secondary objectives of the study will include the following. (1) Other common measures of diagnostic performance of CT-QFR, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) at the patient level compared with FFR as the reference standard. (2) Correlation between CT-QFR and FFR. (3) The comparison of the discrimination ability between CT-QFR, CCTA-derived percent	Page 5,6

		diameter stenosis (CTA-DS%), and QCA-derived DS% for identifying physiologically significant stenosis with FFR as the reference standard.	
<b>METHODS</b>			
<i>Study design</i>	<b>5</b>	Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study): This study is an investigator-initiated, prospective, single-center clinical trial to validate the diagnostic performance of on-site CT-QFR using FFR as the reference standard. The study is conducted in accordance with the ethical principles of the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Huadong Hospital Affiliated to Fudan University. Before the study starts, written informed consent form will be obtained from patients willing to participate in the study and approved by the institutional review board/independent ethics committee of Huadong Hospital Affiliated to Fudan University.	Page 5
<i>Participants</i>	<b>6</b>	Eligibility criteria : Inclusion criteria are: (1) at least 1 lesion with DS% between 30% and 90% in a coronary artery with a $\geq 2.0$ mm reference vessel diameter by visual estimation; (2) invasive coronary angiography performed less than 30 days after CCTA; (3) age over 35 years but less than or equal to 85 years. Exclusion criteria are: (1) prior percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) of the interrogated lesion; (2) myocardial bridge involved in the interrogated vessel; (3) presence of collateral flow; (4) severe heart failure (NYHA $\geq$ III); (5) known severe renal failure (eGFR $<$ 30 ml/min/1.73m <sup>2</sup> ); (6) contraindicated to use contrast agents, beta blockers, nitrates or adenosine drugs; (7) Recent prior myocardial infarction within 1 month of CCTA; (8) low image quality CCTA or coronary angiography to be assessed such as motion artifacts, poor filling of contrast agent, etc.; (9) any factors that affect the image quality of CCTA and coronary angiography, such as frequent premature contractions, atrial fibrillation, etc.	Page 5, 6
	<b>7</b>	Potentially eligible participants will be identified on their symptoms and results from previous tests.	Page 5
	<b>8</b>	Where and when potentially eligible participants were identified (setting, location and dates): Recruitment has been ongoing at Huadong Hospital Affiliated to Fudan University, Shanghai, China since December 2020.	Page 5,6
	<b>9</b>	Participants formed a consecutive, convenience series.	Page 5
<i>Test methods</i>	<b>10a</b>	Index test: Coronary computed tomography angiography - derived quantitative flow ratio (CT-QFR); Angiography-derived quantitative flow ratio (QFR)	Page 4, 5
	<b>10b</b>	Reference standard: Fractional flow reserve (FFR).	Page 4, 5
	<b>11</b>	Rationale for choosing the reference standard: Fractional flow reserve (FFR) is the current gold standard for evaluating the physiological significance of coronary stenosis in the catheterization laboratory. An FFR-guided revascularization strategy was validated with improved clinical outcomes and cost-effectiveness compared to a traditional invasive coronary angiography-guided strategy.	Page 4
	<b>12a</b>	Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory : The performances of QFR $\leq$ 0.80 and CT-QFR $\leq$ 0.80 predict hemodynamically significant coronary stenosis.	Page11
	<b>12b</b>	Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory: The performance of FFR $\leq$ 0.80 predicts hemodynamically significant coronary stenosis.	Page11
	<b>13a</b>	Clinical information and reference standard results will not be available to the performers/readers of the index test.	Page 7-10
	<b>13b</b>	Clinical information and index test results will not be available to the assessors of the reference standard.	Page 7-10
<i>Analysis</i>	<b>14</b>	Methods for estimating or comparing measures of diagnostic accuracy : The performance of QFR $\leq$ 0.80 and CT-QFR $\leq$ 0.80 for predicting FFR $\leq$ 0.80 will be assessed by using sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (+LR), negative likelihood ratio (-LR), and diagnostic accuracy, together with their 95% confidence intervals (CIs). The ROC curve analysis will be performed to assess area under the curve (AUC) of CT-QFR, QFR, CT-derived %DS and QCA derived %DS for predicting	Page 7-10

1		FFR≤0.80. The ROC curves will be compared by using the DeLong method. A two-side p value <0.05 is considered to indicate statistical significance.	
2			
3	15	How indeterminate index test or reference standard results were handled: When calculating the sample size, the data that could not be completed was included as the dropout rate, which accounted for 15%.	Page 7,8
4			
5			
6	16	How missing data on the index test and reference standard were handled: When calculating the sample size, the data that could not be completed was included as the dropout rate, which accounted for 15%.	Page 7,8
7			
8			
9	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory: Agreements between QFR, CT-QFR, and FFR will be assessed by Bland-Altman plot. The Bland-Altman plot depicts the differences of each pair of measurements versus their mean values with reference lines for the mean difference of all paired measurements. The limits of agreement are defined as mean±1.96 SD of absolute difference	Page 11,12
10			
11			
12			
13			
14			
15			
16	18	Intended sample size and how it was determined: The primary endpoint is the diagnostic accuracy of CT-QFR≤0.8 to identify hemodynamically significant coronary stenosis with FFR≤0.8 as the reference standard. The trial is powered for testing significance of the primary endpoint. The primary null and alternative hypotheses to be tested are H0, diagnostic accuracy of CT-QFR≤0.72, and H1, diagnostic accuracy of CT-QFR > 0.72. Estimates for the sample size calculation are based on the results from the retrospective study of CT-QFR[14], where an accuracy of 87% at patient level was found. In this prospective study, the accuracy is conservatively estimated as 82% for consecutively enrolled patient population, and with a target value set as 72%, which is chosen to be higher than the one in the DeFACTO study[15].The sample size is analysed for paired proportions using the following formula: $N = \frac{[Z_{1-\alpha/2}\sqrt{P_0(1-P_0)} + Z_{1-\beta}\sqrt{P_T(1-P_T)}]^2}{(P_T - P_0)^2}$ With power = 0.90, two-tailed alpha = 0.05, a total of 188 patients with paired CT-QFR and FFR are required to reject the null hypothesis for diagnostic accuracy. To account for incomplete CT-QFR/CT-DS%/FFR/QFR/QCA data of 15% at most, a total of 216 patients need to be enrolled. The major secondary endpoint is to validate the non-inferiority of CT-QFR compared with QFR in the patients without extensively calcified lesions. Analyzed by the enrollment of 216 patients, about 158 patients will be calculated according to the proportion, 26.9%, of extensively calcified lesions from the retrospective study[14]. It will be tested for the capability in achieving the major secondary endpoint. The accuracy of 89.5% for CT-QFR in non-severe calcified lesions[14] and the accuracy of 92.7% for QFR[10] are used to calculate the sample size. We set the non-inferiority threshold as 15%. It will be analyzed by the following formula: $N_T = \frac{(Z_{1-\alpha/2} + Z_{1-\beta})^2 [P_C(1 - P_C) + P_T(1 - P_T)]}{(D - \Delta)^2}$ With power = 0.90, two-tailed alpha = 0.05, a total of 122 patients are required to validate the non-inferiority. To account for incomplete CT-QFR/CTA-DS%/FFR/QFR/QCA data of 15% at most , 141 patients need to be enrolled. Therefore, 158 patients without extensively calcified lesions meet the sample size of the major secondary endpoint. Therefore, the sample size is set as 216 patients to satisfy the requirements for validating both primary and major secondary endpoints.	Page 7,8
17			
18			
19			
20			
21			
22			
23			
24			
25			
26			
27			
28			
29			
30			
31			
32			
33			
34			
35			
36			
37			
38			
39			
40			
41			
42			
43			
44			
45	<b>RESULTS</b>		
46	<i>Participants</i>	19 Flow of participants, using a diagram:	Page 11
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			





20	Baseline demographic and clinical characteristics of participants: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
21a	Distribution of severity of disease in those with the target condition: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
21b	Distribution of alternative diagnoses in those without the target condition: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
22	Time interval and any clinical interventions between index test and reference standard: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
<i>Test results</i>	23 Cross tabulation of the index test results (or their distribution) by the results of the reference standard: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	24 Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals): This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
	25 Any adverse events from performing the index test or the reference standard: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.

**DISCUSSION**

26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability: This is a protocol manuscript. It reports an ongoing research study. The data collection is incomplete.
27	Implications for practice, including the intended use and clinical role of the index test: This study will prospectively validate the diagnostic efficacy of a fast computational approach to derive FFR from coronary CT angiography with can be onsite for the first time. Furthermore, severe calcification will affect the diagnosis of lesions on CT images. It was proved that the presence of extensively calcified lesions influenced the diagnostic accuracy and analysis

Page 12-15



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

variability. Therefore, we intend to avoid the effects of severe calcification so as to define whether CT-QFR is equivalent to QFR. It's also the first time to compare the diagnostic performance of CCTA-derived QFR with angiography-derived QFR.

This study will lay the foundation for future studies to look at the potential value of CT-QFR technology in patients management. If the study achieves the expected objectives, outpatients can receive coronary artery functional evaluation while undergoing CCTA Examination. It can greatly reduce unnecessary invasive coronary angiography and coronary interventions.

**OTHER INFORMATION**

28	Registration number and name of registry: ClinicalTrials.gov Identifier: NCT04665817	Page 5
29	Where the full study protocol can be accessed: This is the protocol manuscript.	
30	Sources of funding and other support; role of funders: CAREER Study is an investigator-initiated clinical trial with external funding from Clinical Research Plan of SHDC (No. SHDC2020CR3024B) issued by Shanghai Hospital Development Center, Research Fund of Huadong Hospital (No. 2019lc015) and a Center of Geratic Coronary Artery Disease.	Page 15

For peer review only



# STARD 2015

---

## AIM

STARD stands for “Standards for Reporting Diagnostic accuracy studies”. This list of items was developed to contribute to the completeness and transparency of reporting of diagnostic accuracy studies. Authors can use the list to write informative study reports. Editors and peer-reviewers can use it to evaluate whether the information has been included in manuscripts submitted for publication.

---

## EXPLANATION

A **diagnostic accuracy study** evaluates the ability of one or more medical tests to correctly classify study participants as having **atarget condition**. This can be a disease, a disease stage, response or benefit from therapy, or an event or condition in the future. A medical test can be an imaging procedure, a laboratory test, elements from history and physical examination, a combination of these, or any other method for collecting information about the current health status of a patient.

The test whose accuracy is evaluated is called **index test**. A study can evaluate the accuracy of one or more index tests. Evaluating the ability of a medical test to correctly classify patients is typically done by comparing the distribution of the index test results with those of the **reference standard**. The reference standard is the best available method for establishing the presence or absence of the target condition. An accuracy study can rely on one or more reference standards.

If test results are categorized as either positive or negative, the cross tabulation of the index test results against those of the reference standard can be used to estimate the **sensitivity** of the index test (the proportion of participants *with* the target condition who have a positive index test), and its **specificity** (the proportion *without* the target condition who have a negative index test). From this cross tabulation (sometimes referred to as the contingency or “2x2” table), several other accuracy statistics can be estimated, such as the positive and negative **predictive values** of the test. Confidence intervals around estimates of accuracy can then be calculated to quantify the statistical **precision** of the measurements.

If the index test results can take more than two values, categorization of test results as positive or negative requires a **test positivity cut-off**. When multiple such cut-offs can be defined, authors can report a receiver operating characteristic (ROC) curve which graphically represents the combination of sensitivity and specificity for each possible test positivity cut-off. The **area under the ROC curve** informs in a single numerical value about the overall diagnostic accuracy of the index test.

The **intended use** of a medical test can be diagnosis, screening, staging, monitoring, surveillance, prediction or prognosis. The **clinical role** of a test explains its position relative to existing tests in the clinical pathway. A replacement test, for example, replaces an existing test. A triage test is used before an existing test; an add-on test is used after an existing test.

Besides diagnostic accuracy, several other outcomes and statistics may be relevant in the evaluation of medical tests. Medical tests can also be used to classify patients for purposes other than diagnosis, such as staging or prognosis. The STARD list was not explicitly developed for these other outcomes, statistics, and study types, although most STARD items would still apply.

---

## DEVELOPMENT

This STARD list was released in 2015. The 30 items were identified by an international expert group of methodologists, researchers, and editors. The guiding principle in the development of STARD was to select items that, when reported, would help readers to judge the potential for bias in the study, to appraise the applicability of the study findings and the validity of conclusions and recommendations. The list represents an update of the first version, which was published in 2003.

More information can be found on <http://www.equator-network.org/reporting-guidelines/stard>.

